[{"text": "EXEL Industries: First quarter 2024\u20132025 sales down 19.0% EXEL INDUSTRIES Tue, Jan 28, 2025, 10:04 AM 3 min read In This Article: EXE.PA 0.00% EXEL INDUSTRIES First quarter 2024-2025 revenue down 19.0% First quarter impacted by a downturn in agricultural sales, but other activities holding up well 3-month revenue (October 2024-December 2024)) 2023-2024 2024-2025 Change (reported) Change (LFL*) Reported Reported \u20acm % \u20acm % AGRICULTURAL SPRAYING 90.9 62.2 -28.8 -31.6% -28.7 -31.6% SUGAR BEET HARVESTING 27.1 19.1 -8.0 -29.4% -8.0 -29.5% LEISURE 11.1 12.9 +1.8 +16.3% +1.2 +10.7% INDUSTRY 71.0 67.8 -3.2 -4.5% -3.2 -4.6% EXEL Industries Group 200.1 162.0 -38.1 -19.0% -38.8 -19.4% * Like-for-like (LFL) = at constant consolidation scope and foreign exchange rates First quarter 2024-2025 revenue The EXEL Industries Group posted revenue of \u20ac162.0 million for the first quarter of the 2024-2025 fiscal year, down 19.0% as reported and 19.4% at constant foreign exchange rates and scope . AGRICULTURAL SPRAYING DOWN 31.6% Agricultural Spraying sales showed an expected decline of 31.6% as reported, penalized by low volumes and a challenging business climate. This downturn follows two exceptional years in the agricultural equipment sector, and business now seems to be returning to a more traditional seasonal pattern. Business is returning to the level of the 2021\u20132022 fiscal year. Revenue was down in the Group\u2019s main regions, namely Europe, North America and Australia. SUGAR BEET HARVESTING DOWN 29.4% Sugar Beet Harvesting sales were down compared with the first quarter of the 2023-2024 fiscal year, which was particularly strong with a catch-up in deliveries related to the previous fiscal year. The slight time lag between production schedule and actual sales should be resolved in the second quarter of 2024-2025. LEISURE UP 16.3% In the first quarter, sales in the Garden division improved across all main Group regions, particularly France and the United Kingdom. Distributor inventory levels remain relatively low, with pre-season sales better than last year and in line with expectations. INDUSTRY DOWN 4.5% Industry revenue for the first quarter of the 2024\u20132025 fiscal year was stable year-on-year, except for a slight downturn in Asia, particularly in electrostatics. On the other hand, in Europe, and particularly in Western Europe, as well as in North America, sales remained buoyant. 2025 outlook AGRICULTURAL SPRAYING After two exceptional years, business has returned to a normal seasonal pattern. The level of order intake has fallen significantly over the past fiscal year, with less long-term visibility than in the previous three years, calling for a degree of caution. Production capacities have been adjusted to the level of activity, and the Group remains vigilant with regard to changes in its cost structure. However, the agricultural equipment market cycle, particularly in Europe, seems to have reached its lowest point, with improving prospects. Story Continues SUGAR BEET HARVESTING The order book is solid at the end of the first quarter, and the outlook is well-oriented for the year. In 2025, priority continues to be given to developing the after-sales activity with enriched services to better support its customers in using its products. LEISURE The outlook for the Garden division is encouraging, with early pre-season sales up on 2023\u20132024 and lower distributor inventory levels. These factors should lead to a better pre-season overall than last year. The Nautical market remains challenging, with distributor inventories still high. Having completed production in fall 2024, the Wauquiez 55 was presented at the D\u00fcsseldorf boat show in January 2025 and generated a lot of interest. INDUSTRY In Industrial Spraying, business is expected to remain healthy in 2025, particularly in North America. Over the remainder of the fiscal year, the Group will continue to develop and modernize its plants, particularly at Stains (France). In Technical Hoses, the Group is pursuing the development of its product ranges and continues to focus on innovation and sustainability, by increasing the proportion of recycled PVC in its hoses. Daniel Tragus, Chief Executive Officer of the EXEL Industries Group \u201cEXEL Industries had a mixed first quarter on the back of two years with a very high basis of comparison, but which nevertheless reflected the solidity of its business model. In the agricultural sector, despite the anticipated decline in volumes, the business climate presents more favorable prospects for the coming months. Pre-season Garden sales are encouraging, while Industry sales have held up well. The Group closely monitors the evolution of its activities and adapts its cost structure for the rest of the fiscal year.\u00a0As a reminder, the first quarter is not very representative due to the seasonality of our activities.\u201d Upcoming events February 4, 2025 : Annual General Meeting April 29, 2025, before market opening: Q2 2024-2025 revenue May 23, 2025, before market opening: H1 2024-2025 results and investor presentation Attachment EXEL Industries_Press release_2024-2025-Q1 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EXEL", "date": "2025-01-28T07:04:00+00:00", "sentiment": {"score": -0.9667603252455592, "confidence": 0.9747280478477478, "probabilities": {"positive": 0.007967722602188587, "negative": 0.9747280478477478, "neutral": 0.017304278910160065}}, "embedding": [0.005624070297926664, -0.058207012712955475, 0.05124181881546974, 0.0020220940932631493, 0.07917927950620651, 0.007204856723546982, -0.03354582190513611, 0.11466264724731445, -0.02422826923429966, 0.05783353000879288, 0.16769784688949585, 0.014292333275079727, -0.04391627758741379, 0.04401739686727524, 0.016249123960733414, -0.017702631652355194, -0.04045799374580383, -0.022023487836122513, -0.1502998173236847, -0.028529321774840355, 0.11850810796022415, 0.006077195517718792, -0.04611615836620331, -0.0061022331938147545, -0.049534883350133896, -0.0049351174384355545, -0.1377147138118744, -0.034587014466524124, -0.20855119824409485, -0.0898243859410286, -0.10020346939563751, 0.28708723187446594, -0.029123183339834213, -0.08097649365663528, 0.03983217477798462, -0.05982675403356552, -0.003420156892389059, -0.025035947561264038, 0.08361399173736572, -0.05774511396884918, -0.03748807683587074, -0.15575414896011353, -0.08152982592582703, -0.1304847002029419, -0.06874822080135345, -0.006466317921876907, 0.05858364701271057, 0.032730262726545334, -0.05241042748093605, 0.04046095907688141, 0.05405022203922272, 0.008696295320987701, -0.005126659758388996, -0.047493331134319305, 0.04443977028131485, -0.041382014751434326, 0.05605098605155945, 0.00358082284219563, -0.032335057854652405, 0.00933205708861351, -0.05159727483987808, -0.038486383855342865, -0.05521996319293976, -0.036972954869270325, 0.02946108765900135, -0.07099824398756027, -0.08404119312763214, -0.04814985767006874, -0.1403176486492157, -0.047257907688617706, 0.03845437616109848, -0.18344774842262268, -0.1219339594244957, -0.08571935445070267, -0.01321161538362503, 0.10835173726081848, 0.1358540952205658, 0.09892706573009491, 0.03979826718568802, -0.13121110200881958, 0.11346783488988876, 0.06897033751010895, -0.09059840440750122, -0.1663375049829483, -0.11037438362836838, -0.07023826241493225, 0.16260117292404175, 0.02835235372185707, 0.24005988240242004, 0.055932868272066116, 0.05221699923276901, -0.013615635223686695, -0.057532988488674164, 0.08416298031806946, 0.010800205171108246, 0.008265949785709381, -0.004798749461770058, 0.004007238894701004, 0.08273583650588989, 0.1060597151517868, 0.02266201190650463, 0.07851074635982513, -0.005703267641365528, -0.07853692024946213, -0.16821438074111938, -0.16118833422660828, 0.021851874887943268, 0.07226601243019104, -0.057366207242012024, -0.040613576769828796, -0.12749439477920532, 0.013764969073235989, -0.008717052638530731, -0.12056013941764832, -0.11164344847202301, 0.05619604513049126, -0.04202394187450409, -0.1376972496509552, 0.047266148030757904, -0.05376732721924782, 0.14797121286392212, 0.1569710671901703, -0.0503610298037529, 0.13082750141620636, 0.12801891565322876, 0.050241030752658844, 0.002412976697087288, 1.0639769650013033e-32, -0.05194826424121857, -0.04375893622636795, -0.0489373654127121, -0.06677647680044174, -0.020056460052728653, 0.0713774710893631, 0.0056875888258218765, 0.06734015047550201, 0.06586438417434692, -0.105414979159832, -0.10247816145420074, 0.10929492861032486, -0.04915306344628334, 0.03264002129435539, 0.11190377175807953, -0.07727979123592377, 0.04900232329964638, 0.0887380987405777, 0.1118927001953125, 0.08929122984409332, -0.03697897493839264, -0.09036030620336533, -0.07256480306386948, 0.060283467173576355, 0.01668371446430683, 0.15770605206489563, -0.013261117041110992, -0.0416659452021122, 0.001877436414361, 0.048565685749053955, 0.2243843376636505, 0.0111004039645195, 0.0022958130575716496, -0.06746923923492432, -0.11150889098644257, -0.04475472867488861, 0.0021511197555810213, -5.5797863751649857e-05, 0.017458589747548103, -0.04230383411049843, -0.04964820295572281, 0.16490989923477173, -0.016733501106500626, 0.033143654465675354, -0.002819579327479005, -0.04404931887984276, 0.076761394739151, 0.0281984843313694, 0.07419703900814056, 0.044593796133995056, 0.05191878229379654, 0.0577847994863987, 0.05945596471428871, -0.01679886505007744, 0.12382136285305023, 0.09394105523824692, -0.04355282336473465, -0.06902922689914703, -0.02276412770152092, 0.02999630570411682, -0.011849923059344292, 0.18513286113739014, -0.0020129000768065453, -0.06505995988845825, -0.01212248858064413, 0.07469746470451355, 0.12950509786605835, 0.1048007383942604, -0.048216626048088074, 0.039219409227371216, -0.05963519960641861, -0.09793855249881744, 0.10941079258918762, -0.043234601616859436, 0.06938265264034271, -0.0037952607963234186, 0.08686043322086334, 0.040007419884204865, -0.0327155664563179, -0.021955955773591995, -0.06514991074800491, 0.015433162450790405, -0.06551647931337357, -0.09909036755561829, -0.04193784296512604, 0.02085760235786438, 0.055182017385959625, 0.014249696396291256, 0.10470041632652283, -0.019932454451918602, -0.09629720449447632, -0.007700995076447725, -0.09021348506212234, 0.1685238629579544, 0.07035437226295471, -9.962943512696577e-33, 0.025762256234884262, 0.17507047951221466, -0.04786652699112892, 0.00041121477261185646, -0.034685615450143814, -0.008913098834455013, 0.05792921036481857, -0.0038767727091908455, -0.024563923478126526, 0.01723855920135975, -0.09650185704231262, 0.035891540348529816, -0.027997275814414024, 0.05156341567635536, -0.10209255665540695, -0.04764002934098244, 0.10119292885065079, -0.0038633858785033226, -0.0056233275681734085, 0.008214127272367477, -0.059080712497234344, 0.23546940088272095, -0.04975832998752594, -0.02061106078326702, -0.07111946493387222, 0.10208749026060104, -0.11019822955131531, 0.09991420805454254, 0.0047536492347717285, -0.18722465634346008, -0.01587851718068123, -0.05845573544502258, -0.07955631613731384, 0.09412333369255066, -0.06526889652013779, -0.09666752070188522, -0.015243789181113243, -0.07033296674489975, 0.03822292760014534, 0.0364098958671093, 0.0493035651743412, 0.023705556988716125, 0.0013084281235933304, 0.024665657430887222, -0.007541272323578596, -0.0612468495965004, 0.015621457248926163, -0.04184984415769577, 0.17306748032569885, 0.02043953910470009, 0.027255231514573097, 0.1274615377187729, -0.14249415695667267, 0.0032318036537617445, -0.02894538640975952, 0.0035231499932706356, 0.1447913497686386, -0.05327785015106201, -0.23764243721961975, 0.031084537506103516, 0.045511599630117416, 0.11182612180709839, 0.13033056259155273, -0.060386333614587784, 0.06849195808172226, -0.014116976410150528, 0.07233783602714539, -0.060736313462257385, 0.17146432399749756, -0.045352429151535034, -0.003574322909116745, 0.046473242342472076, -0.03995015472173691, -0.08470958471298218, -0.026867700740695, 0.12770673632621765, 0.015686742961406708, -0.07279670238494873, -0.01568281464278698, -0.06150597333908081, -0.03174842894077301, 0.0035703680478036404, 0.06395909935235977, -0.007746148854494095, -0.08785496652126312, -0.025112055242061615, -0.11168475449085236, -0.0479370653629303, 0.059270646423101425, 0.05004862695932388, -0.16923215985298157, -0.06723462790250778, 0.06851990520954132, 0.13481757044792175, 0.07323195040225983, -9.970875680664903e-08, -0.01007930003106594, 0.020439133048057556, 0.06334947049617767, 0.11692071706056595, 0.11992122232913971, -0.10960724949836731, 0.016068726778030396, 0.13215509057044983, 0.05690111964941025, -0.014411289244890213, -0.001635105349123478, 0.039893969893455505, -0.08056583255529404, 0.06874384731054306, 0.03173187002539635, 0.020786244422197342, -0.05187205970287323, -0.022923972457647324, -0.09818178415298462, -0.046541471034288406, -0.03007146157324314, 0.06909126043319702, -0.06207386404275894, -0.08558705449104309, -0.024333355948328972, -0.10079486668109894, -0.01686081849038601, 0.03624863922595978, 0.03885548561811447, 0.02960857003927231, 0.07298313826322556, -8.125230669975281e-05, 0.05502438545227051, -0.0657457634806633, -0.0912538468837738, -0.13315510749816895, -0.07580113410949707, 0.003128611482679844, -0.017561210319399834, 0.08919718116521835, 0.0016537168994545937, -0.042903557419776917, -0.024177633225917816, -0.003169836476445198, -0.022001272067427635, -0.07560698688030243, -0.14981913566589355, -0.08295993506908417, 0.09612537175416946, -0.05682969465851784, 0.03434465453028679, 0.012751888483762741, 0.015421031974256039, 0.009188435971736908, 0.04131532832980156, 0.03046235255897045, -0.0611623153090477, -0.0838167816400528, 0.02402719296514988, 0.029021166265010834, -0.020875515416264534, -0.15068429708480835, 0.010168788023293018, 0.08990953117609024], "changes": {"1wk": 0.8589037027606473}}, {"text": "Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform Zacks Equity Research Mon, Jan 27, 2025, 8:36 PM 5 min read In This Article: EXEL -0.81% Shares of Exelixis EXEL were down 5.13% on Jan. 24, following a downgrade in rating by analysts at Oppenheimer. Oppenheimer downgraded EXEL to \u201cPerform\u201d from \u201cOutperform\u201d as the analysts were concerned about the potential differentiation of pipeline candidate zanzalintinib versus cabozantinib following the abstract for STELLAR-001 study at American Society of Clinical Oncology 2025 Gastrointestinal Cancers Symposium (ASCO GI). While Oppenheimer believes data from STELLAR-001 likely derisk the late-stage STELLAR-303 study in metastatic colorectal cancer (CRC), the firm does not necessarily see clear differentiation for zanzalintinib. Hence, it chooses to be on the sidelines for now while awaiting additional clarity. Shares of Exelixis have surged 47.9% in a year against the industry\u2019s decline of 12.4%. Zacks Investment Research Image Source: Zacks Investment Research Exelixis More on EXEL\u2019s STELLAR-303 study On Jan. 25, Exelixis announced results from an expansion cohort of the phase Ib/II STELLAR-001 study evaluating zanzalintinib alone or in combination with Tecentiq (atezolizumab) in patients with previously treated metastatic CRC at the ASCO GI. This cohort of the STELLAR-001 trial included 107 patients randomized equally to receive single-agent zanzalintinib or zanzalintinib in combination with atezolizumab. Patients had unresectable, locally advanced or metastatic RAS wild-type CRC that was non-microsatellite instability-high or non-mismatch repair-deficient. Both progression-free survival and overall survival (OS) were numerically improved by the addition of atezolizumab to zanzalintinib. We note that STELLAR-001 is a global, open-label phase Ib/II study of zanzalintinib as a single agent or in combination with atezolizumab in patients with inoperable locally advanced or metastatic solid tumors. The trial is divided into two parts \u2014 a dose-escalation stage and an expansion cohort stage. The expansion cohorts evaluating zanzalintinib (100 mg) as a single agent or in combination with atezolizumab also include patients with clear cell renal cell carcinoma (RCC), non-clear cell RCC, breast cancer that is hormone receptor-positive and HER-2 negative and castration-resistant prostate cancer. In the overall population arm, the data showed an objective response rate (ORR) of 7.4% for the combination arm and an ORR of 1.9% for zanzalintinib arm. In patients without liver metastasis (NLM), ORR was 18% for the combination arm and 5.9% for the standalone zanzalintinib arm. Oppenheimer cited that the data are overall positive and support the design of phase III STELLAR-303 in metastatic CRC with primary OS analysis in NLM patients. In addition, data from prior trials, including LEAP-017, suggest liver metastases may reduce the benefit of immunotherapy. Story Continues However, per Oppenheimer, the data didn't particularly stand out from prior phase I/II studies of cabozantinib in combination with checkpoint inhibitors in similar settings. Consequently, Oppenheimer is concerned about the differentiations of zanzalintinib and whether it can replace cabozantinib in key indications. EXEL Announces CABINET Study Data at ASCO GI Exelixis announced results from a subgroup analysis of the phase III CABINET pivotal study of patients with extra-pancreatic neuroendocrine tumors (epNET) arising in the gastrointestinal (GI) tract. The analysis showed that cabozantinib was associated with an improvement in progression-free survival compared with placebo in patients with advanced GI neuroendocrine tumors (NET), a subgroup of the epNET cohort. EXEL\u2019s Focus on Cabometyx Label Expansion EXEL\u2019s lead drug, Cabometyx (cabozantinib), is a leading tyrosine kinase inhibitor (\u201cTKI\u201d) for the treatment of RCC. The use of the drug in combination with Bristol Myers\u2019 BMY Opdivo in the first-line setting is boosting sales. BMY\u2019s Opdivo is one of the leading immuno-oncology drugs, and it has been approved for various oncology indications. EXEL is looking to expand Cabometyx. The FDA accepted EXEL\u2019s supplemental new drug application for cabozantinib for patients with previously treated advanced pancreatic neuroendocrine tumors (pNET) and those with previously treated advanced epNET. It assigned a standard review with a target action date of April 3, 2025. The FDA also granted the orphan drug designation to cabozantinib for the treatment of pNET. EXEL is looking to reduce its dependence on Cabometyx with the development of zanzalintinib, a next generation oral TKI. Another study, STELLAR-304, is evaluating zanzalintinib in combination with Opdivo versus sunitinib in previously untreated patients with advanced non-clear cell RCC. Exelixis recently collaborated with pharma giant Merck MRK to evaluate zanzalintinib in combination with its blockbuster anti-PD-1 therapy Keytruda (pembrolizumab) in a late-stage study for treating patients with head and neck squamous cell carcinoma (\u201cHNSCC\u201d). Per the agreement, Merck will supply Keytruda for the ongoing, Exelixis-sponsored phase III STELLAR-305 study in previously untreated PD-L1-positive recurrent or metastatic HNSCC. Data from the phase II portion is expected to be available in the second half of 2025. Exelixis also expects to initiate a late-stage study, STELLAR-311, in the first half of 2025 evaluating zanzalintinib compared with everolimus as a first oral therapy in patients with advanced NET, regardless of the site of origin. Per the collaboration with Merck, two RCC studies are also planned for 2025 and updates on the same will be provided later. EXEL\u2019s Zacks Rank & A Key Pick EXEL currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Immunocore Holdings plc IMCR, which sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here . In the past 90 days, estimates for Immunocore\u2019s 2024 loss per share have narrowed from $1.80 to 94 cents. Loss per share estimates for 2025 have narrowed from $2.33 to $1.66 during the same time frame. IMCR\u2019s earnings beat estimates in two of the trailing four quarters and missed the same in the other two, the average surprise being 25.57%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Exelixis, Inc. (EXEL) : Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EXEL", "date": "2025-01-27T17:36:00+00:00", "sentiment": {"score": -0.784384474158287, "confidence": 0.8497269153594971, "probabilities": {"positive": 0.06534244120121002, "negative": 0.8497269153594971, "neutral": 0.08493059873580933}}, "embedding": [-0.0347454771399498, -0.13143734633922577, -0.09409373253583908, 0.013084002770483494, -0.024564187973737717, -0.22154021263122559, -0.030682146549224854, 0.26202836632728577, 0.1163814514875412, -0.013278508558869362, -0.0832236260175705, 0.15118807554244995, 0.1299837827682495, 0.02753080241382122, -0.11690783500671387, 0.037645287811756134, 0.09927501529455185, 0.02330751344561577, -0.08078200370073318, 0.14786915481090546, -0.07160485535860062, -0.07695512473583221, 0.22060994803905487, 0.040862541645765305, -0.04680728539824486, -0.07508618384599686, -0.12444886565208435, 0.13281658291816711, -0.17149069905281067, -0.08706596493721008, 0.11211095750331879, 0.10449960827827454, -0.0015678536146879196, -0.009150121361017227, 0.04256623610854149, -0.015439463779330254, -0.062057990580797195, 0.08688317984342575, -0.14406023919582367, -0.04408307746052742, 0.029303796589374542, -0.02827550657093525, -0.11459306627511978, -0.0474432036280632, -0.051783159375190735, -0.26377931237220764, -0.20581799745559692, -0.061802998185157776, 0.034253641963005066, 0.2903761565685272, -0.19636677205562592, -0.09959416091442108, 0.0012888363562524319, 0.2963373064994812, 0.08938733488321304, 0.014322273433208466, -0.12453771382570267, 0.021311797201633453, 0.040629997849464417, 0.05369888246059418, 0.026114769279956818, -0.10828253626823425, -0.020312577486038208, -0.01992926560342312, 0.11009544134140015, 0.10540493577718735, 0.0036682230420410633, -0.14011026918888092, -0.10066559910774231, 0.006449261214584112, 0.09598196297883987, -0.055123403668403625, 0.01837902143597603, 0.05611851066350937, -0.1805121749639511, 0.08156947791576385, 0.2438506782054901, 0.08342017233371735, -0.049891598522663116, -0.00415029376745224, 0.025646887719631195, 0.10106819868087769, 0.04265621304512024, -0.14513498544692993, -0.03941916301846504, 0.0627884566783905, -0.050820477306842804, 0.16247446835041046, 0.13046282529830933, 0.09517882764339447, 0.12329153716564178, 0.1265106499195099, 0.04268897697329521, -0.024365127086639404, 0.10177312791347504, -0.08062303811311722, -0.07476998120546341, -0.08037649095058441, 0.057194072753190994, -0.00883021205663681, 0.02912304177880287, -0.047202304005622864, -0.024599481374025345, -0.10024887323379517, 0.0017246855422854424, -0.10172213613986969, 0.008822306990623474, 0.02048824541270733, -0.13593916594982147, 0.005455316975712776, 0.02923395484685898, -0.06751696765422821, 0.10142325609922409, 0.0018182187341153622, -0.07141785323619843, 0.24979792535305023, -0.038284655660390854, 0.006996848154813051, 0.05011565238237381, 0.006173097528517246, -0.026195161044597626, 0.07647554576396942, 0.05075665935873985, -0.06418606638908386, 0.1682545393705368, 0.20065806806087494, -0.11404921114444733, 1.4084256094038287e-32, 0.0006043728208169341, -0.017727933824062347, 0.040252089500427246, 0.17464397847652435, -0.018309656530618668, 0.09871852397918701, 0.05503362417221069, 0.02728615701198578, -0.12519340217113495, -0.10846259444952011, -0.053025923669338226, 0.022910185158252716, 0.1713666021823883, 0.06965504586696625, -0.18317103385925293, -0.0668346956372261, 0.014411285519599915, -0.03694240748882294, -0.15291628241539001, 0.03695213049650192, 0.014390970580279827, -0.020868908613920212, -0.035770125687122345, -0.04790841415524483, -0.05598131939768791, 0.15134763717651367, -0.060239214450120926, 0.1672714352607727, -0.010459105484187603, 0.005334238521754742, -0.0739443451166153, 0.014798273332417011, 0.08935137093067169, -0.09115179628133774, -0.048039644956588745, 0.08606525510549545, -0.013582605868577957, -0.031798891723155975, 0.08975885808467865, 0.06604337692260742, -0.04648527503013611, 0.04636242240667343, -0.14724469184875488, -0.0006160023622214794, 0.03839026018977165, -0.19334104657173157, -0.0004036305472254753, -0.020268375054001808, 0.08021759986877441, -0.048661477863788605, 0.02479897439479828, -0.0862109512090683, -0.08252398669719696, -0.04503750801086426, -0.20215466618537903, 0.04796517640352249, -0.16684174537658691, -0.037768371403217316, 0.08882580697536469, 0.02801114320755005, 0.0675322636961937, 0.029186179861426353, -0.03754638135433197, 0.013227693736553192, 0.03430499508976936, 0.09644510596990585, -0.04238542914390564, -0.044358085840940475, -0.13528960943222046, 0.07722051441669464, -0.12882979214191437, -0.013850769028067589, 0.27556556463241577, 0.09314070641994476, 0.1603020280599594, -0.07974573224782944, 0.033559806644916534, 0.04460043087601662, 0.037892237305641174, 0.14981962740421295, -0.1640196144580841, -0.07188813388347626, -0.09017333388328552, 0.16319000720977783, -0.13868339359760284, -0.046175867319107056, -0.03389938548207283, 0.08871077001094818, -0.028730187565088272, -0.012124755419790745, 0.13010399043560028, -0.13677749037742615, -0.1283612847328186, 0.04927387088537216, 0.036568865180015564, -1.4466100740223522e-32, -0.003381301648914814, 0.09671631455421448, 0.02263791672885418, -0.059753190726041794, -0.03751619905233383, 0.07663804292678833, 0.036501139402389526, -0.1148102730512619, 0.012336764484643936, -0.18637216091156006, 0.05409013479948044, 0.2449285089969635, 0.046766798943281174, -0.1765020489692688, -0.09986916184425354, 0.03157659247517586, -0.17269858717918396, -0.005128862336277962, -0.017023850232362747, -0.021693192422389984, 0.0365927591919899, 0.020932726562023163, -0.09511419385671616, 0.0033731572329998016, -0.14273852109909058, 0.1929084062576294, 0.16393248736858368, 0.04527720808982849, -0.0022402536123991013, -0.017261307686567307, -0.03713539242744446, 0.11030159890651703, -0.265277624130249, -0.03815344721078873, 0.023764625191688538, 0.04785408079624176, -0.11364515870809555, -0.17464721202850342, -0.07474519312381744, -0.09015108644962311, -0.0645277202129364, 0.12816230952739716, -0.020892689004540443, -0.07442039996385574, 0.03214650973677635, -0.008123594336211681, 0.14012163877487183, -0.08697783946990967, 0.09296007454395294, -0.047546520829200745, -0.011593064293265343, 0.16817671060562134, -0.03588603809475899, 0.060711223632097244, 0.004274321720004082, -0.015336370095610619, 0.015346622094511986, -0.01362040638923645, -0.14184316992759705, 0.12867334485054016, 0.01516740396618843, 0.20322385430335999, 0.17225125432014465, 0.05676066130399704, 0.08707309514284134, 0.1228618249297142, 0.11639465391635895, -0.022495683282613754, 0.04350806400179863, -0.06315834075212479, -0.03311522305011749, -0.10628056526184082, -0.049099214375019073, -0.10161353647708893, 0.056346409022808075, 0.2303047478199005, -0.07875826954841614, -0.04378044605255127, -0.16323110461235046, 0.01568653993308544, 0.03603814169764519, -0.07345148921012878, -0.04903111606836319, 0.0566452220082283, -0.04130373150110245, 0.11314007639884949, -0.08025220036506653, -0.0110592320561409, 0.0025610309094190598, -0.02559007704257965, -0.09754355251789093, -0.1370207965373993, -0.04917342588305473, -0.015214089304208755, -0.03526618704199791, -1.0099838476662626e-07, 0.02272200956940651, 0.008233093656599522, 0.03601178526878357, -0.023732773959636688, 0.0156254880130291, 0.02761063724756241, -0.06915552914142609, -2.8058886528015137e-05, 0.009409591555595398, 0.14711780846118927, 0.021115314215421677, 0.12997709214687347, -0.08981598913669586, -0.06258079409599304, -0.09868184477090836, 0.009873274713754654, -0.020278440788388252, -0.037928506731987, -0.035269845277071, 0.1900026500225067, -0.17200054228305817, -0.03966519981622696, 0.00846034474670887, -0.12518933415412903, 0.04837169498205185, -0.042375598102808, 0.026793422177433968, 0.1866675317287445, -0.026568245142698288, -0.06902144104242325, -0.02523425966501236, -0.057961102575063705, 0.05515887588262558, -0.006097225472331047, -0.0003751814365386963, -0.014903232455253601, 0.10451368242502213, 0.018166355788707733, -0.010635128244757652, 0.2505365312099457, 0.10392123460769653, -0.014567427337169647, -0.01746373251080513, -0.04670882225036621, -0.16117152571678162, -0.0039658755995333195, -0.1913170963525772, -0.0750449001789093, 0.04734654724597931, -0.06508979201316833, 0.008526043966412544, 0.03676809370517731, -0.15380537509918213, -0.08725979179143906, -0.09673752635717392, 0.03685205429792404, -0.09667104482650757, 0.009355712682008743, -0.012674643658101559, -0.0037772003561258316, 0.026275286450982094, -0.22015929222106934, -0.012835141271352768, 0.006829235702753067], "changes": {"1wk": 0.4582998105005692}}, {"text": "PREMIUM Exelixis' Revenue Growth Likely to Be Meaningfully Ahead of Consensus, Morgan Stanley Says MT Newswires Mon, Jan 27, 2025, 7:18 PM 1 min read Exelixis' (EXEL) revenue growth in the coming years is expected to be meaningfully ahead of market e PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EXEL", "date": "2025-01-27T16:18:55+00:00", "sentiment": {"score": 0.07711122557520866, "confidence": 0.08845295011997223, "probabilities": {"positive": 0.08845295011997223, "negative": 0.011341724544763565, "neutral": 0.9002053141593933}}, "embedding": [-0.23966076970100403, -0.15968872606754303, -0.04085418954491615, 0.02999032847583294, 0.05642686411738396, -0.15937158465385437, 0.03813200816512108, 0.0650392547249794, 0.06380544602870941, 0.01429383922368288, 0.14687715470790863, 0.1648995578289032, -0.004823543131351471, -0.040766965597867966, 0.2313363403081894, -0.023561501875519753, 0.07315285503864288, -0.1262495070695877, -0.03309377282857895, 0.03247237205505371, -0.060323093086481094, -0.1588425487279892, 0.009519785642623901, -0.06028636544942856, 0.13623575866222382, -0.03938096761703491, -0.17011071741580963, -0.02321304753422737, -0.006901879794895649, -0.13255910575389862, -0.04698314890265465, -0.009809182025492191, 0.15443086624145508, -0.07556873559951782, -0.027566513046622276, -0.17250359058380127, 0.09800998866558075, 0.07346949726343155, 0.01133816596120596, -0.08570225536823273, 0.04181904345750809, -0.19888612627983093, -0.28945231437683105, -0.09377146512269974, -0.04067176580429077, -0.16628144681453705, 0.06295164674520493, 0.16085004806518555, -0.13672341406345367, 0.1085011288523674, -0.037595756351947784, -0.15945948660373688, 0.11202255636453629, -0.11934374272823334, -0.03048035129904747, -0.014922484755516052, -0.1647273302078247, -0.13280467689037323, 0.05455838516354561, -0.0285745058208704, -0.061645712703466415, -0.16953490674495697, -0.1005246564745903, 0.11569301038980484, -0.02844238094985485, 0.10609734058380127, 0.15669099986553192, 0.09226148575544357, -0.12567241489887238, -0.09932476282119751, -0.1073567345738411, -0.03272896632552147, 0.0027844817377626896, -0.03164161369204521, 0.09893297404050827, 0.21675099432468414, 0.22144019603729248, 0.02309342846274376, 0.07734271138906479, -0.05205807462334633, 0.11229313164949417, 0.003186156740412116, -0.09626071900129318, -0.08477914333343506, 0.030637267976999283, -0.11566882580518723, 0.04181278124451637, -0.026178041473031044, -0.02906939387321472, -0.06850646436214447, 0.08035417646169662, -0.07827752083539963, -0.1350560039281845, 0.22349710762500763, -0.011499245651066303, 0.1128825917840004, -0.2401839643716812, -0.23396003246307373, -0.07959539443254471, 0.04564625769853592, 0.10035298764705658, 0.08715353906154633, -0.07307318598031998, 0.04915427416563034, 0.017122771590948105, -0.2977316975593567, 0.05481579527258873, 0.2212325483560562, 0.07648894935846329, -0.01965409517288208, -0.04172302410006523, -0.12919120490550995, -0.0056048110127449036, -0.16311076283454895, -0.11934039741754532, 0.172342911362648, -0.20818732678890228, 0.09480966627597809, 0.10823200643062592, -0.027596980333328247, 0.1276485174894333, 0.3109610974788666, -0.05551927909255028, 0.01683614030480385, 0.10504812747240067, 0.03458210453391075, 0.019885357469320297, 1.338816654304773e-32, -0.11644543707370758, 0.10362929850816727, 0.0946395993232727, -0.015011806972324848, 0.08938650041818619, 0.13281866908073425, -0.0166214220225811, -0.009866520762443542, -0.14824092388153076, -0.1614096313714981, -0.14331693947315216, 0.24480773508548737, 0.004700289107859135, 0.11067277938127518, 0.12208378314971924, -0.14595600962638855, -0.1473735272884369, 0.09420306980609894, 0.1724778562784195, 0.013793477788567543, 0.2482999563217163, -0.3174026608467102, -0.04724202677607536, -0.05166733264923096, -0.04912891611456871, 0.09645218402147293, 0.10526146739721298, 0.06157749518752098, 0.08655709773302078, 0.12407324463129044, -0.12692543864250183, 0.05790834501385689, -0.08693176507949829, -0.0501546785235405, -0.055533234030008316, 0.218322291970253, -0.07440643012523651, -0.10140202194452286, 0.13536442816257477, -0.11047441512346268, -0.05446827784180641, 0.11004496365785599, -0.17376668751239777, -0.06670500338077545, -0.15647932887077332, 0.006535081658512354, 0.016729068011045456, -0.121543750166893, 0.18153341114521027, -0.05304494872689247, 0.06286168098449707, 0.04809898883104324, -0.16176795959472656, -0.003979987930506468, 0.05465998128056526, 0.16404689848423004, -0.04834040626883507, 0.0602300763130188, 0.09916598349809647, -0.12931767106056213, 0.06356104463338852, 0.04324071481823921, 0.010672547854483128, -0.06283067911863327, -0.16547183692455292, 0.3495780825614929, 0.07890807092189789, -0.05243547633290291, -0.15897543728351593, 0.13728198409080505, 0.20071479678153992, 0.03989368677139282, -0.017348241060972214, -0.043082237243652344, -0.06296811997890472, 0.05534874647855759, -0.0780443474650383, -0.004881435073912144, 0.11761035025119781, 0.2887178361415863, 0.0673004612326622, -0.017680231481790543, 0.042361658066511154, -0.06350966542959213, 0.048079777508974075, -0.03690334036946297, 0.04000711441040039, 0.10078365355730057, 0.1137724295258522, -0.07634595781564713, 0.052233513444662094, -0.10519454628229141, -0.1929345279932022, 0.20343582332134247, -0.06776387244462967, -1.5440278459156046e-32, 0.05161547288298607, 0.10994533449411392, 0.04253740236163139, -0.019537854939699173, -0.15926969051361084, -0.06983581185340881, -0.14929665625095367, 0.3103744089603424, 0.12739147245883942, 0.21559415757656097, -0.022950630635023117, 0.23054949939250946, 0.01848929561674595, 0.09138540178537369, 0.014970232732594013, -0.1494750678539276, 0.03069889172911644, -0.17538276314735413, 0.0522226057946682, -0.08727096021175385, -0.03277967497706413, -0.02196754887700081, -0.22019052505493164, 0.2212962657213211, 0.18697373569011688, -0.05885382369160652, -0.023206353187561035, 0.2172669917345047, -0.11782126873731613, -0.23492740094661713, -0.08639902621507645, -0.05724767595529556, -0.12003809958696365, -0.04908192157745361, 0.05860484763979912, -0.03710755333304405, 0.10060577839612961, 0.02332419343292713, -0.04025746509432793, -0.057460613548755646, 0.09873189777135849, -0.08501753956079483, 0.0027207552921026945, -0.10811932384967804, 0.1211426705121994, -0.0006823822041042149, 0.04913607984781265, 0.014076902531087399, 0.13018573820590973, -0.024719443172216415, 0.008621050976216793, 0.20038898289203644, -0.023037215694785118, 0.08699530363082886, -0.15548105537891388, 0.07960782200098038, -0.03287647292017937, 0.13560926914215088, -0.15137550234794617, -0.0779518261551857, 0.0013607809087261558, 0.2224884331226349, 0.01069923397153616, 0.0015002606669440866, -0.035063836723566055, -0.10785757005214691, 0.19172045588493347, -0.11994216591119766, 0.08569413423538208, -0.02463349886238575, 0.17574729025363922, -0.08552684634923935, -0.3546629548072815, -0.18550512194633484, -0.010610455647110939, 0.24035504460334778, 0.06425413489341736, -0.05092946067452431, -0.032430458813905716, -0.15632693469524384, 0.12326911836862564, -0.015185041353106499, 0.06224152073264122, 0.0900130644440651, -0.08249180018901825, -0.14591264724731445, 0.1613137573003769, -0.17120756208896637, -0.062424544245004654, 0.02261163294315338, -0.16016338765621185, -0.2264050543308258, -0.19929388165473938, 0.015729838982224464, 0.06167891249060631, -1.0035137165687047e-07, 0.033810246735811234, 0.06386379897594452, -0.04858837276697159, 0.1369415521621704, 0.061541855335235596, -0.015655774623155594, -0.023852158337831497, -0.023112352937459946, 0.09701603651046753, 0.0703250914812088, 0.09285486489534378, -0.1011192724108696, 0.005876425188034773, 0.025544660165905952, 0.03296998143196106, 0.019298866391181946, -0.046309955418109894, -0.08874283730983734, -0.030698124319314957, -0.16592499613761902, -0.000759364222176373, 0.1603485494852066, 0.262591153383255, -0.16476985812187195, 0.042186617851257324, -0.07782317698001862, 0.07723556458950043, -0.08799665421247482, 0.042305488139390945, -0.10928454250097275, -0.13416080176830292, -0.004463421646505594, -0.10378175228834152, -0.025028808042407036, -0.0766143947839737, -0.029002567753195763, -0.11763400584459305, 0.09769538789987564, 0.02781054377555847, 0.12945415079593658, 0.0796172022819519, -0.11230383068323135, 0.15209996700286865, -0.0054484037682414055, -0.11962070316076279, 0.053885333240032196, -0.1924332231283188, -0.09750460833311081, 0.1586974859237671, -0.15933845937252045, 0.10427329689264297, -0.05680515617132187, 0.09582823514938354, -0.06802206486463547, -0.05548425391316414, 0.023688938468694687, -0.1077272817492485, 0.024279432371258736, -0.03785129263997078, 0.14207330346107483, 0.1920282393693924, -0.23618057370185852, 0.05293493717908859, 0.16427269577980042], "changes": {"1wk": 0.4582998105005692}}, {"text": "PREMIUM Truist Lifts Price Target on Exelixis to $43 From $42, Keeps Buy Rating MT Newswires Mon, Jan 27, 2025, 3:33 PM In This Article: EXEL -0.81% Exelixis (EXEL) has an average rating of overweight and mean price target of $36.24, according to an PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EXEL", "date": "2025-01-27T12:33:53+00:00", "sentiment": {"score": 0.10015164501965046, "confidence": 0.11111482232809067, "probabilities": {"positive": 0.11111482232809067, "negative": 0.010963177308440208, "neutral": 0.877921998500824}}, "embedding": [-0.1076720580458641, -0.05259376019239426, -0.01952708698809147, 0.19966824352741241, 0.06651517748832703, -0.18810243904590607, 0.17006060481071472, 0.14137372374534607, 0.06115967407822609, -0.010566008277237415, 0.24298661947250366, -0.09302518516778946, 0.030629565939307213, -0.10603030025959015, 0.18795549869537354, -0.027309898287057877, 0.18575899302959442, -0.02844090946018696, -0.06527537107467651, 0.03862855210900307, -0.0462271124124527, -0.02684692293405533, 0.017103077843785286, 0.0015755231725052, 0.1451580822467804, -0.12637197971343994, -0.19511450827121735, -0.024432694539427757, 0.005256268661469221, -0.19921410083770752, -0.03482779860496521, -0.05577583983540535, 0.03580375388264656, -0.11446437984704971, -0.07899770140647888, -0.13404715061187744, -0.04010402038693428, 0.015390620566904545, -0.15118251740932465, -0.10849019140005112, 0.07363152503967285, -0.0540931262075901, -0.28908658027648926, -0.1058245301246643, -0.2320549339056015, -0.16447772085666656, 0.03226117044687271, 0.2197234034538269, -0.020590681582689285, 0.16600896418094635, -0.06621576845645905, -0.11480895429849625, 0.1169130876660347, -0.10750766098499298, -0.03759023919701576, 0.00242376746609807, -0.11905812472105026, -0.058666955679655075, 0.04416672885417938, -0.024890068918466568, 0.006985535845160484, -0.033901721239089966, -0.1319386065006256, 0.027750495821237564, 0.03980674967169762, 0.016781151294708252, 0.05006486922502518, -0.0778723806142807, -0.045007895678281784, -0.01616884581744671, -0.02337859757244587, -0.013421173207461834, 0.08670674264431, 0.03542099893093109, 0.13437029719352722, 0.25467437505722046, 0.0883018746972084, -0.14408347010612488, -0.03348330035805702, 0.11345124989748001, 0.06584250926971436, -0.1478123515844345, 0.005798147991299629, -0.09349135309457779, 0.2881965637207031, -0.17910510301589966, 0.13159799575805664, 0.07583843916654587, 0.008164952509105206, 0.06875455379486084, 0.11191456764936447, -0.12001760303974152, -0.15994273126125336, 0.1704055517911911, 0.010106009431183338, 0.11655309051275253, -0.19896435737609863, -0.08095744252204895, -0.19905364513397217, 0.015882428735494614, 0.07517514377832413, 0.042045433074235916, -0.03136518597602844, 0.15827150642871857, -0.06341969221830368, -0.3475996255874634, 0.07430613040924072, 0.1423042267560959, 0.02257935330271721, -0.0797305703163147, -0.1582968682050705, -0.2074485719203949, 0.029986076056957245, -0.1406477838754654, -0.13660624623298645, 0.1193036139011383, -0.08198902755975723, -0.008955065160989761, 0.019935498014092445, -0.18440191447734833, -0.009753321297466755, 0.16883455216884613, -0.019061272963881493, 0.07878604531288147, 0.04554355517029762, -0.025466986000537872, -0.09069059789180756, 1.0918704908571562e-32, 0.0025794566608965397, 0.14160293340682983, -0.0021201076451689005, -0.14327901601791382, 0.04966948553919792, 0.05122525617480278, -0.061461981385946274, 0.020855246111750603, -0.13698536157608032, -0.005935204215347767, -0.09003852307796478, 0.16299158334732056, 0.028245948255062103, 0.18990327417850494, 0.19844946265220642, -0.1500399112701416, -0.15527211129665375, 0.1553686261177063, 0.164641335606575, 0.029709849506616592, 0.06919576972723007, -0.15047812461853027, -0.09378932416439056, -0.11917850375175476, -0.18683938682079315, 0.15749138593673706, 0.046216025948524475, 0.08212902396917343, 0.05966053903102875, 0.08025573194026947, -0.12290021032094955, -0.030827712267637253, -0.010015913285315037, -0.024303480982780457, -0.02390381693840027, 0.1082155779004097, -0.04673279449343681, -0.06757470965385437, -0.0049962569028139114, -0.11337751895189285, -0.024154340848326683, 0.13003362715244293, -0.06420043855905533, -0.051216546446084976, -0.09488008171319962, 0.04270587116479874, 0.053916845470666885, -0.21402405202388763, 0.14564566314220428, -0.03173959255218506, -0.015244103036820889, 0.11097072809934616, -0.10563010722398758, 0.10501562058925629, -0.05520941689610481, 0.08381212502717972, -0.02571178786456585, 0.08530867844820023, 0.08397643268108368, -0.08178985118865967, 0.005076965317130089, 0.10703331232070923, 0.13159003853797913, -0.12957754731178284, -0.09788405150175095, 0.230333611369133, -0.022423425689339638, -0.11289364099502563, -0.28284066915512085, 0.21203412115573883, 0.1418033391237259, 0.09954331070184708, 0.16565832495689392, -0.08259199559688568, -0.03889474645256996, 0.0152432294562459, -0.09872661530971527, -0.08753141760826111, 0.13417747616767883, 0.10619693994522095, 0.016357094049453735, -0.03284968435764313, 0.06925727427005768, -0.080144502222538, 0.028244659304618835, -0.004938616883009672, -0.15418744087219238, 0.02533099241554737, 1.4557838767359499e-05, -0.023670867085456848, 0.11521933972835541, -0.07356826961040497, -0.33251121640205383, 0.06042054668068886, 0.004947690758854151, -1.1748968323500852e-32, -0.004116198047995567, 0.1481771618127823, 0.16459240019321442, 0.02015209011733532, -0.09747973084449768, 0.05125357583165169, -0.19178397953510284, 0.24280941486358643, 0.19612395763397217, 0.23850075900554657, -0.10802638530731201, 0.17493902146816254, -0.026437636464834213, 0.1606874167919159, 0.04638682305812836, -0.06406260281801224, -0.05988123640418053, -0.10315486043691635, 0.0669555589556694, -0.25266408920288086, -0.07028734683990479, 0.147549107670784, -0.10397396981716156, 0.29918208718299866, 0.11196738481521606, -0.022438419982790947, 0.10710661113262177, 0.16602785885334015, -0.07122232019901276, -0.29628050327301025, -0.020977787673473358, -0.004552570171654224, -0.053049761801958084, 0.04868864640593529, -0.08599402755498886, 0.059006042778491974, 0.09733805060386658, 0.14111317694187164, 0.009242238476872444, -0.03299897909164429, 0.07811670750379562, -0.04087279736995697, 0.09900069236755371, -0.12183952331542969, 0.16537369787693024, -0.14366482198238373, 0.05310249328613281, -0.1609509140253067, 0.14437685906887054, -0.012925710529088974, 0.036111168563365936, 0.1267031580209732, 0.049665290862321854, 0.1674213707447052, -0.14135625958442688, -0.03921092301607132, -0.10233017802238464, 0.15727642178535461, -0.13039915263652802, -0.1127738505601883, 0.06421217322349548, 0.2766142785549164, -0.02987971156835556, 0.0018725647823885083, -0.023940468207001686, -0.031896643340587616, 0.14907000958919525, -0.046472277492284775, -0.025519678369164467, -0.020179681479930878, -0.009627280756831169, -0.09697265177965164, -0.0998365506529808, -0.07401847094297409, 0.08415942639112473, 0.1222066879272461, 0.059858500957489014, 0.0003554286959115416, 0.0056993733160197735, -0.12386896461248398, 0.16113930940628052, -0.10350807011127472, 0.09400870651006699, -0.04291197285056114, -0.03244860842823982, -0.07440365850925446, 0.035498566925525665, 0.08065806329250336, -0.016302436590194702, 0.14283517003059387, -0.12031962722539902, -0.07861502468585968, -0.0174463652074337, -0.013393058441579342, 0.026674784719944, -9.988486482370718e-08, 0.023629505187273026, 0.037652235478162766, -0.0681886076927185, 0.13757088780403137, -0.04417639598250389, 0.0659593790769577, 0.00582844577729702, 0.002433585235849023, -0.02545103244483471, 0.0607089102268219, 0.03547696769237518, -0.1575995534658432, -0.05363426357507706, 0.08568210899829865, -0.03460680693387985, -0.20040525496006012, -0.10006961971521378, 0.051021624356508255, -0.003077665576711297, -0.10032051801681519, -0.04511737450957298, 0.17504334449768066, 0.2337081879377365, -0.032240837812423706, 0.037427868694067, 0.060187600553035736, 0.04662127047777176, -0.0995037853717804, 0.1360858827829361, 0.04008791968226433, -0.14792846143245697, 0.013330234214663506, -0.10093967616558075, 0.06659788638353348, -0.10933662950992584, 0.011657685972750187, -0.14919154345989227, 0.0941036120057106, -0.14133775234222412, 0.2302413284778595, 0.11725995689630508, -0.13206054270267487, 0.011404945515096188, -0.0195941012352705, -0.026142971590161324, 0.20157532393932343, -0.3389149308204651, -0.14224836230278015, 0.1856168955564499, -0.012429924681782722, 0.15189014375209808, 0.03672334551811218, 0.029872190207242966, 0.07908390462398529, -0.1576358824968338, -0.10068771243095398, -0.13616040349006653, 0.056046418845653534, -0.07438009977340698, 0.1705303192138672, 0.19527235627174377, -0.3147013485431671, 0.02318531461060047, 0.248394176363945], "changes": {"1wk": 1.2832324763725946}}, {"text": "PREMIUM Morgan Stanley Upgrades Exelixis to Overweight From Equalweight, Raises Price Target to $40 From $30 MT Newswires Mon, Jan 27, 2025, 2:19 PM In This Article: EXEL -0.81% Exelixis (EXEL) has an average rating of overweight and mean price target of $36.19, according to an PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EXEL", "date": "2025-01-27T11:19:22+00:00", "sentiment": {"score": 0.0728732030838728, "confidence": 0.08456133306026459, "probabilities": {"positive": 0.08456133306026459, "negative": 0.011688129976391792, "neutral": 0.9037505388259888}}, "embedding": [-0.10505243390798569, -0.06166844815015793, -0.030474793165922165, 0.24637646973133087, 0.08419828861951828, -0.2051733136177063, 0.10347501933574677, 0.14576852321624756, 0.031189948320388794, 0.05378257855772972, 0.18386314809322357, -0.13785678148269653, -0.07270259410142899, -0.1023314893245697, 0.23309262096881866, -0.11410520225763321, 0.23658744990825653, 0.06699776649475098, -0.13994906842708588, 0.07697742432355881, 0.004845575895160437, -0.10293325036764145, -0.0010076160542666912, 0.09118524193763733, 0.097481869161129, -0.14038871228694916, -0.2187076359987259, -0.07640468329191208, -0.07300858944654465, -0.14534148573875427, -0.04301239922642708, -0.1173432469367981, 0.02756381593644619, -0.11860065907239914, -0.04653032496571541, -0.17305296659469604, 0.1144464910030365, 0.058320049196481705, -0.12241064012050629, -0.23087677359580994, -0.05414309352636337, -0.0175679512321949, -0.259463369846344, -0.057329338043928146, -0.18519160151481628, -0.0896955356001854, 0.014688407070934772, 0.24357275664806366, 0.06210499256849289, 0.11658968776464462, -0.10722176730632782, -0.13102833926677704, 0.07570278644561768, -0.21650663018226624, 0.04826467111706734, 0.08721418678760529, -0.11406152695417404, -0.15669959783554077, 0.06079714000225067, -0.0657067522406578, -0.019406508654356003, -0.07421126961708069, -0.0256130900233984, 0.14034079015254974, 0.016355767846107483, 0.07972846925258636, 0.0389024093747139, -0.1359817534685135, -0.04524267837405205, -0.03030293807387352, 0.06975426524877548, -0.1344153881072998, 0.07823973894119263, -0.05483401194214821, 0.20762105286121368, 0.2710590958595276, 0.08454317599534988, -0.17513816058635712, 0.00746086286380887, 0.11570016294717789, 0.008434785529971123, -0.09001082181930542, 0.03113740310072899, -0.05916031822562218, 0.34929358959198, -0.1861339509487152, 0.13603194057941437, 0.05361156910657883, 0.04840398579835892, 0.1318214386701584, 0.1163504347205162, -0.14403463900089264, -0.15271742641925812, 0.21552571654319763, -0.05555218085646629, 0.09648311883211136, -0.2969253957271576, -0.08320938795804977, -0.21741420030593872, 0.043750591576099396, 0.07390834391117096, 0.09040150791406631, 0.07688060402870178, 0.2196798026561737, 0.015960538759827614, -0.3220992982387543, 0.14260277152061462, 0.11019548773765564, 0.09488309174776077, -0.08063076436519623, -0.01557274628430605, -0.1864505261182785, 0.0900602713227272, -0.10274894535541534, -0.2060348391532898, 0.13099518418312073, 0.009827964939177036, -0.0044626835733652115, -0.06882894784212112, -0.09604614973068237, -0.07162020355463028, 0.19912585616111755, -0.08484651148319244, 0.03346608951687813, -0.046213213354349136, -0.042634859681129456, -0.1167740672826767, 9.093828540104672e-33, -0.14624673128128052, 0.11259821802377701, 0.14838261902332306, -0.15914730727672577, 0.159060537815094, -0.007340898271650076, 0.04175892099738121, -0.01502647902816534, -0.1592722237110138, -0.058460336178541183, -0.11281681060791016, 0.20249181985855103, 0.06340210139751434, 0.23031838238239288, 0.10574623197317123, -0.24671034514904022, -0.14241431653499603, 0.19355270266532898, 0.19953607022762299, 0.07174613326787949, 0.06803889572620392, -0.30272141098976135, -0.04372767359018326, -0.1471744179725647, -0.08416067063808441, 0.1741952747106552, 0.10881137102842331, 0.12678104639053345, 0.1339067965745926, 0.06866690516471863, -0.16393443942070007, -0.02248135767877102, 0.0160501878708601, -0.023146726191043854, -0.1073141023516655, 0.025987768545746803, -0.04345490038394928, -0.06216000020503998, 0.037719015032052994, -0.022294964641332626, 0.000687741267029196, 0.1791650503873825, -0.07211117446422577, -0.09242720156908035, -0.10036863386631012, 0.14628994464874268, 0.013569550588726997, -0.08563272655010223, 0.07828231900930405, -0.07351316511631012, -0.0009299014345742762, 0.07635045051574707, -0.1437952220439911, 0.12846042215824127, -0.11695928126573563, 0.10077165812253952, -0.01288205198943615, 0.1018543466925621, 0.13931535184383392, -0.05575814098119736, 0.026694372296333313, 0.15457099676132202, 0.06845277547836304, -0.06988896429538727, -0.027680227532982826, 0.30952009558677673, -0.10967791080474854, -0.13457708060741425, -0.29317235946655273, 0.2303597778081894, 0.21462039649486542, 0.05904284492135048, 0.11029721051454544, -0.007910729385912418, 0.01452851016074419, 0.04739870876073837, -0.19214561581611633, -0.04118401184678078, 0.06963873654603958, 0.08950230479240417, 0.027358010411262512, 0.11784987151622772, 0.1014922708272934, -0.037057675421237946, 0.0040012747049331665, -0.018658017739653587, -0.21233488619327545, 0.08334984630346298, 0.04615768790245056, -0.011747537180781364, 0.1532854288816452, -0.21802379190921783, -0.32190313935279846, 0.08292986452579498, -0.08366188406944275, -9.312739383690368e-33, 0.014641011133790016, 0.06295979022979736, 0.18369418382644653, -0.05551578477025032, -0.10772284865379333, -0.05674637109041214, -0.13897395133972168, 0.1050950214266777, 0.22714868187904358, 0.2276199460029602, -0.0720696672797203, 0.12165853381156921, -0.08782362937927246, 0.18248337507247925, 0.03877062350511551, -0.08523906767368317, -0.08042240142822266, -0.030484594404697418, 0.034560661762952805, -0.2876793444156647, 0.013458894565701485, 0.1397208869457245, -0.09273291379213333, 0.2624708116054535, 0.1956363320350647, 0.013989062048494816, 0.1048203781247139, 0.3238427937030792, -0.09151232987642288, -0.368190735578537, -0.11993671953678131, 0.04305928200483322, -0.07433708012104034, 0.025459429249167442, -0.07347257435321808, 0.1282341331243515, 0.11071747541427612, 0.03190304711461067, 0.058682844042778015, -0.005548498593270779, 0.08603213727474213, -0.11199074238538742, 0.02437056414783001, -0.11041302978992462, 0.2281389832496643, -0.13254530727863312, 0.01744501292705536, -0.22474312782287598, 0.20042665302753448, -0.07529398053884506, -0.041268300265073776, 0.03681563585996628, 0.026517318561673164, 0.2538714110851288, -0.15469807386398315, -0.012355188839137554, 0.025939803570508957, 0.14772731065750122, -0.12763141095638275, -0.239132821559906, -0.042692460119724274, 0.26507246494293213, 0.048653360456228256, -0.014011867344379425, -0.04209047183394432, -0.021927224472165108, 0.18871501088142395, -0.21606507897377014, 0.02283206209540367, 0.00998267438262701, -0.009303508326411247, -0.08130094408988953, -0.034893158823251724, -0.04240589216351509, 0.07631109654903412, 0.17298613488674164, 0.1447322517633438, 0.0007201574044302106, -0.024178320541977882, -0.21389071643352509, 0.12361998856067657, -0.26184284687042236, 0.1887252926826477, 0.11911708861589432, -0.028182927519083023, -0.05004310607910156, 0.09486814588308334, 0.06441211700439453, -0.10702894628047943, 0.23062364757061005, -0.14213062822818756, -0.06703181564807892, 0.034620728343725204, 0.018565338104963303, 0.07627294212579727, -9.961346592035625e-08, 0.015343180857598782, 0.053956761956214905, -0.1209336370229721, 0.12459069490432739, -0.0228984784334898, 0.09474124759435654, -0.0434688925743103, -0.010906997136771679, 0.0006075212731957436, 0.0280191320925951, 0.07682713866233826, -0.07341662794351578, 0.05933161452412605, 0.030045367777347565, -0.16656789183616638, -0.1278194934129715, -0.1702388972043991, -0.04730018973350525, 0.017384525388479233, -0.16952845454216003, -0.06432297825813293, 0.1747916042804718, 0.1592104434967041, -0.07771862298250198, 0.05098897963762283, -0.04295971244573593, 0.044123560190200806, -0.07670561969280243, 0.09046909958124161, -0.050255876034498215, -0.15841315686702728, -0.03556196019053459, -0.05747435241937637, 0.12640753388404846, 0.0030129053629934788, -0.11095840483903885, -0.18016032874584198, 0.1545046716928482, -0.11611637473106384, 0.2219398468732834, 0.039480578154325485, -0.16366225481033325, 0.012851783074438572, -0.05047229304909706, 0.07465909421443939, 0.18153132498264313, -0.4744100570678711, 0.014328595250844955, 0.11335896700620651, -0.075686514377594, 0.23530453443527222, 0.09401243180036545, -0.013821030966937542, 0.10421113669872284, -0.23382233083248138, -0.03164919838309288, -0.19771452248096466, 0.12735725939273834, -0.12585417926311493, 0.24315212666988373, 0.2026892453432083, -0.3830334544181824, -0.010634770616889, 0.20610524713993073], "changes": {"1wk": 1.2832324763725946}}, {"text": "Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025 Business Wire Sat, Jan 25, 2025, 6:00 PM 9 min read In This Article: EXEL -0.81% \u2013 In a subgroup analysis of patients without liver metastases, adding atezolizumab to zanzalintinib led to enhanced progression-free survival and overall survival \u2013 ALAMEDA, Calif., January 25, 2025 --( BUSINESS WIRE )-- Exelixis, Inc. (Nasdaq: EXEL) today announced results from an expansion cohort of the phase 1b/2 STELLAR-001 trial evaluating zanzalintinib alone or in combination with atezolizumab (Tecentriq \u00ae ) in patients with previously-treated metastatic colorectal cancer (CRC). The findings will be presented during Poster Session C: Cancers of the Colon, Rectum and Anus, at 7:00 a.m. PT on January 25 at the American Society of Clinical Oncology 2025 Gastrointestinal Cancers Symposium (ASCO GI 2025). This cohort of the STELLAR-001 trial included 107 patients randomized 1:1 to receive single-agent zanzalintinib or zanzalintinib in combination with atezolizumab. Patients had unresectable, locally advanced or metastatic RAS wild-type CRC that was non-microsatellite instability-high or non-mismatch repair-deficient. The median number of prior lines of therapy was 3.0 for patients treated with zanzalintinib alone and 2.5 for patients treated with zanzalintinib in combination with atezolizumab. Thirty-two percent and 31% of patients did not have liver metastases in baseline scans, respectively. Both progression-free survival (PFS) and overall survival (OS) were numerically improved by the addition of atezolizumab to zanzalintinib. Detailed efficacy results of the overall population and the subgroup analysis of patients without liver metastases are in Table 1 below. TABLE 1 Zanzalintinib alone Zanzalintinib + atezolizumab Overall population Patients, n 53 54 Median follow-up, months 19.2 18.9 Median PFS, months 3.0 4.0 PFS HR (95% CI) 0.65 (0.42-0.99) Median OS, months 11.1 11.7 OS HR (95% CI) 0.89 (0.56-1.42) ORR, % 1.9 7.4 Partial response, n 1 4 Patients without liver metastases Patients, n 17 17 Median PFS, months 3.3 8.2 PFS HR (95% CI) 0.37 (0.15-0.91) Median OS, months 21.1 18.5 OS HR (95% CI) 0.74 (0.27-2.04) 6-month survival rate, % 64.7 87.8 12-month survival rate, % 52.3 62.7 ORR, % 5.9 18.0 Partial response, n 1 3 CI: confidence interval; HR: hazard ratio; ORR: objective response rate; OS: overall survival; PFS: progression-free survival. In a biomarker analysis, a PD-L1 combined positive score greater than 1 was associated with improved PFS and OS in patients treated with zanzalintinib in combination with atezolizumab versus zanzalintinib alone. \"This cohort of the STELLAR-001 trial was designed to inform the contribution of atezolizumab to zanzalintinib in patients with previously treated metastatic colorectal cancer,\" said Amy Peterson, M.D., Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer, Exelixis. \"Data from this randomized expansion cohort reaffirms our decision to initiate STELLAR-303 evaluating zanzalintinib in combination with atezolizumab compared with regorafenib in patients with metastatic colorectal cancer, which completed enrollment in August 2024, and we anticipate data from that trial in the second half of 2025, dependent on study event rates.\" Story Continues Detailed safety results for the overall population are in Table 2 below. Grade 3/4 treatment-related adverse events (AEs) occurred in 40% of patients receiving zanzalintinib alone and 48% of patients receiving zanzalintinib in combination with atezolizumab. One grade 5 treatment-related AE occurred in each group, both of which were also determined by investigator as related to the disease under study. Zanzalintinib was discontinued in 19% of patients receiving zanzalintinib alone and 30% of patients receiving zanzalintinib in combination with atezolizumab. Treatment-related AEs leading to discontinuation of any drug occurred in 8% and 19% of patients, respectively. TABLE 2 Zanzalintinib alone Zanzalintinib + atezolizumab Any Grade Grade 3/4 Any Grade Grade 3/4 Most Common TRAE, % Nausea 36 6 54 0 Diarrhea 49 8 52 9 Fatigue 21 4 43 11 Hypertension 30 13 19 7 Other TRAE, % Proteinuria 17 0 13 0 Palmar-plantar erythrodysesthesia 11 0 6 0 Stomatitis 2 2 6 0 TRAE: treatment-related adverse event About STELLAR-001 STELLAR-001 (NCT03845166) is a global, open-label phase 1b/2 study of zanzalintinib as a single agent or in combination with atezolizumab in patients with inoperable locally advanced or metastatic solid tumors. The trial is divided into two parts: a dose-escalation stage and an expansion cohort stage. The expansion cohorts evaluating zanzalintinib (100 mg) as a single agent or in combination with atezolizumab also include patients with clear cell renal cell carcinoma (RCC), non-clear cell RCC, breast cancer that is hormone receptor-positive and HER-2 negative and castration-resistant prostate cancer. More information about the trial is available at ClinicalTrials.gov . About STELLAR-303 The global phase 3 pivotal study, STELLAR-303, is evaluating zanzalintinib (100 mg) in combination with atezolizumab compared with regorafenib in patients with metastatic, refractory non-microsatellite instability-high or non-mismatch repair-deficient CRC. The primary endpoint in the study is OS in patients without active liver metastases. If OS is positive in the population of patients without liver metastases, the study will evaluate OS in the intent-to-treat population that includes patients with and without liver metastases. The study completed enrollment in the third quarter of 2024, and preliminary results are expected in the second half of 2025, dependent on study event rates. More information about the trial is available at ClinicalTrials.gov . About Zanzalintinib Zanzalintinib is a third-generation oral tyrosine kinase inhibitor that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis and resistance to multiple therapies, including immune checkpoint inhibitors. With zanzalintinib, Exelixis sought to build upon its extensive experience with the target profile of cabozantinib, the company\u2019s flagship medicine, while improving key characteristics, including pharmacokinetic half-life. Zanzalintinib is currently being developed for the treatment of advanced solid tumors, including genitourinary, colorectal and head and neck cancers. A phase 3 pivotal trial evaluating zanzalintinib compared with everolimus as a first oral therapy in patients with advanced neuroendocrine tumors (NET), regardless of site of origin, is expected to be initiated in the first half of 2025. About CRC Colorectal cancer is the third most common cancer and the second leading cause of cancer-related deaths in the U.S. 1 Approximately 154,000 new cases will be diagnosed in the U.S. with around 53,000 expected deaths from the disease in 2025. 1 Colorectal cancer is most frequently diagnosed among people aged 65-74 and is more common in men and in people of non-Hispanic American Indian/Alaska Native descent. 2 Nearly a quarter of colorectal cancer cases are diagnosed at the metastatic stage, at which point the five-year survival rate is just 15.7%. 2 About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX \u00ae (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com , follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements related to: the presentation of data from STELLAR-001 at ASCO GI 2025; the expectation for initial clinical data readouts from STELLAR-303 in the second half of 2025, dependent on study event rates; the therapeutic potential of zanzalintinib, both alone and in combination with atezolizumab, in patients with metastatic CRC; and Exelixis\u2019 scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis\u2019 current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the availability of data at the referenced times; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere; Exelixis\u2019 continuing compliance with applicable legal and regulatory requirements; the potential failure of zanzalintinib, both alone and in combination with atezolizumab to demonstrate safety and/or efficacy in STELLAR-001, STELLAR-303 and in future clinical testing; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating zanzalintinib; the costs of conducting clinical trials; Exelixis\u2019 dependence on third-party vendors for the development, manufacture and supply of zanzalintinib; Exelixis\u2019 ability to protect its intellectual property rights; market competition; changes in economic and business conditions; and other factors affecting Exelixis and its development programs detailed from time to time under the caption \"Risk Factors\" in Exelixis\u2019 most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis\u2019 future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law. Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis. TECENTRIQ (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group. _________________ 1 Key Statistics for Colorectal Cancer. ACS. Available at: https://www.cancer.org/cancer/types/colon-rectal-cancer/about/key-statistics.html . Accessed January 2025. 2 Cancer Stat Facts: Colorectal Cancer. SEER. Available at: https://seer.cancer.gov/statfacts/html/colorect.html . Accessed January 2025. View source version on businesswire.com: https://www.businesswire.com/news/home/20250124233353/en/ Contacts Investors Contact: Susan Hubbard EVP, Public Affairs and Investor Relations Exelixis, Inc. 650-837-8194 shubbard@exelixis.com Media Contact: Stekki Millman Senior Director, Public Affairs Exelixis, Inc. 650-837-7187 smillman@exelixis.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EXEL", "date": "2025-01-25T15:00:00+00:00", "sentiment": {"score": 0.4986003953963518, "confidence": 0.5255365967750549, "probabilities": {"positive": 0.5255365967750549, "negative": 0.026936201378703117, "neutral": 0.4475271999835968}}, "embedding": [-0.0442453995347023, -0.13123628497123718, -0.10702427476644516, 0.028573408722877502, 0.012375387363135815, -0.18648356199264526, -0.04837625473737717, 0.21403378248214722, 0.08378785848617554, -0.05312071740627289, -0.05919201672077179, 0.07721226662397385, 0.14556482434272766, -0.003940015099942684, -0.17346906661987305, 0.08798356354236603, 0.10347656905651093, 0.044100794941186905, -0.04670119285583496, -0.0003613363951444626, -0.14875537157058716, -0.0755845159292221, 0.2638825476169586, 0.011651546694338322, -0.09550487995147705, -0.08702512830495834, -0.169509619474411, 0.19013819098472595, -0.17715013027191162, -0.07862909883260727, 0.11921720206737518, 0.10527783632278442, -0.059693895280361176, 0.01636664755642414, 0.07528946548700333, -0.0535709485411644, -0.048453912138938904, 0.12400083988904953, -0.25160688161849976, -0.08589038252830505, -0.008278601802885532, -0.008466134779155254, -0.10129117965698242, -0.043994173407554626, -0.007141381502151489, -0.3099813461303711, -0.18115945160388947, -0.024632133543491364, 0.051088158041238785, 0.25586938858032227, -0.15271440148353577, -0.0236220546066761, -0.009122337214648724, 0.3288878798484802, 0.14736425876617432, 0.033331744372844696, -0.07009586691856384, 0.005915550980716944, 0.08721666038036346, 0.003993941005319357, -0.025201382115483284, -0.09944528341293335, 0.0007798699662089348, -0.05708417296409607, 0.14471545815467834, 0.17886702716350555, -0.017171267420053482, -0.19927150011062622, -0.12282799184322357, -0.04581549018621445, -0.015648555010557175, 0.010875723324716091, 0.08312912285327911, 0.11254625022411346, -0.1356150209903717, 0.05642785504460335, 0.173140287399292, 0.09576337784528732, -0.05270582064986229, 0.08734489977359772, -0.061678458005189896, 0.06613656133413315, 0.022872766479849815, -0.1234867051243782, -0.07295772433280945, 0.006625562906265259, -0.09068736433982849, 0.09551595151424408, 0.09643575549125671, 0.005850480869412422, 0.17930027842521667, 0.19616417586803436, 0.13409289717674255, -0.04911781847476959, 0.1636834442615509, -0.12284712493419647, -0.0799114853143692, -0.050136398524045944, 0.0893416479229927, -0.022145897150039673, -0.030870527029037476, -0.07914040982723236, 0.019597690552473068, -0.13222895562648773, 0.019252829253673553, -0.07028535008430481, 0.005054662935435772, 0.058448728173971176, -0.11374060064554214, -0.027286048978567123, 0.08428771793842316, -0.12340310215950012, 0.11270041763782501, 0.025318264961242676, -0.04266201704740524, 0.21870574355125427, 0.0029673411045223475, 0.010707229375839233, 0.0913422480225563, 0.04416028782725334, 0.011209341697394848, 0.031058643013238907, 0.08100125193595886, -0.06530317664146423, 0.21486978232860565, 0.13377799093723297, 0.010492012836039066, 1.358358660140018e-32, 0.023748943582177162, 0.05930476635694504, 0.01831195317208767, 0.1782354861497879, 0.03158062323927879, 0.07994543761014938, 0.09514126181602478, 0.04460394009947777, -0.0758667141199112, -0.11383108049631119, -0.06600771099328995, 0.052573107182979584, 0.1558825522661209, 0.0413234643638134, -0.16095119714736938, -0.05837005376815796, 0.06321258842945099, -0.1399361789226532, -0.21209022402763367, 0.10917173326015472, 0.06119944900274277, -0.0326077900826931, -0.008828073740005493, -0.12005969136953354, -0.027786489576101303, 0.1321646124124527, -0.012254934757947922, 0.15213662385940552, 0.003790970891714096, 0.023361580446362495, -0.14029563963413239, 0.062483351677656174, 0.04458583891391754, -0.026286669075489044, -0.006690039299428463, 0.0690305083990097, 0.007970096543431282, -0.0025074174627661705, 0.05335167795419693, 0.10429884493350983, -0.09200674295425415, 0.011921355500817299, -0.11045221984386444, -0.044495731592178345, 0.09008508175611496, -0.3278803527355194, -0.04788559675216675, 0.03884109482169151, 0.11299385130405426, -0.02272443100810051, 0.04941407963633537, -0.049758754670619965, -0.11158636212348938, -0.0631377249956131, -0.13667786121368408, 0.0015025711618363857, -0.08852469176054001, 0.05029057338833809, 0.08162598311901093, 0.012296013534069061, 0.07880799472332001, -0.1288309544324875, -0.07872150093317032, 0.07589956372976303, 0.07146775722503662, 0.07286851108074188, -0.0761302262544632, -0.025287795811891556, -0.14104759693145752, 0.07128354907035828, -0.08830994367599487, 0.005541890859603882, 0.2548268139362335, 0.15468654036521912, 0.06956841796636581, -0.11009031534194946, 0.09324971586465836, 0.004868621006608009, -0.04841567575931549, 0.12894216179847717, -0.1667180061340332, -0.09714947640895844, -0.19567614793777466, 0.1691822111606598, -0.162761390209198, -0.11719094216823578, -0.0075601194985210896, 0.13815131783485413, -0.10383667051792145, -0.0817548930644989, 0.21778398752212524, -0.11458533257246017, -0.13519427180290222, 0.043558280915021896, 0.021382061764597893, -1.404128442867604e-32, 0.03778896480798721, 0.1522844433784485, -0.0032194408122450113, -0.009683790616691113, 0.02153780125081539, 0.017150714993476868, 0.10863634943962097, -0.08215818554162979, 0.01370915211737156, -0.1834910809993744, 0.04438794031739235, 0.16758239269256592, 0.03113836795091629, -0.11539247632026672, -0.1258164644241333, 0.03127124160528183, -0.07676539570093155, 0.042177364230155945, -0.06872826814651489, 0.00129668228328228, -0.03209096938371658, 0.004418373107910156, -0.021413380280137062, -0.04316554218530655, -0.19106754660606384, 0.18091896176338196, 0.1357685774564743, 0.052757348865270615, -0.12158560752868652, 0.08996723592281342, -0.07370372116565704, 0.1215839684009552, -0.2162332832813263, -0.08790047466754913, 0.10845575481653214, 0.03736848384141922, -0.07146789878606796, -0.22496044635772705, -0.041777193546295166, -0.05657551437616348, -0.07056263834238052, 0.02442035637795925, -0.08450286090373993, -0.04686186835169792, -0.0015189461410045624, 0.10128277540206909, 0.1371355652809143, -0.038292448967695236, 0.05303751677274704, -0.07264206558465958, -0.005747281014919281, 0.21594209969043732, -0.022109124809503555, 0.06010100245475769, -0.02909534052014351, -0.012636527419090271, -0.009589830413460732, 0.030083870515227318, -0.11837884783744812, 0.1313331425189972, 0.009268374182283878, 0.19546456634998322, 0.19524048268795013, 0.0345660001039505, 0.16760024428367615, 0.12807196378707886, 0.1338539719581604, -0.011019662022590637, 0.1110936775803566, 0.0005467529408633709, -0.07102448493242264, -0.04316001385450363, -0.05499851703643799, -0.05000276118516922, 0.0005225576460361481, 0.2333413064479828, -0.028842974454164505, 0.061365820467472076, -0.10922619700431824, 0.003547836095094681, 0.02518134005367756, -0.08476439118385315, -0.011721632443368435, -0.012256947346031666, 0.03186294436454773, 0.0972556620836258, -0.10129342973232269, 0.0052634477615356445, -0.005914842709898949, -0.02963608130812645, 0.009655732661485672, -0.1295294463634491, -0.06365443766117096, 0.0066770827397704124, -0.06475018709897995, -1.005326097924808e-07, 0.027308642864227295, -0.0037496876902878284, -0.10591557621955872, -0.04200245440006256, 0.03167492523789406, 0.054639264941215515, -0.15879881381988525, -0.09793746471405029, -0.01796882413327694, 0.09591741114854813, 0.030018793419003487, 0.08370497822761536, -0.13169944286346436, -0.013469510711729527, -0.05442184954881668, 0.10145525634288788, -0.004079122096300125, -0.06654123216867447, -0.041527196764945984, 0.23422852158546448, -0.201549232006073, -0.08481299877166748, -0.048893582075834274, -0.14115053415298462, 0.0027727484703063965, -0.013403267599642277, -0.05275796353816986, 0.19920523464679718, 0.03313135728240013, -0.07492277771234512, -0.06138885021209717, -0.10460993647575378, -0.003048180602490902, -0.01711263135075569, -0.02780304290354252, 0.03318420797586441, 0.08719872683286667, 0.0057965414598584175, 0.02588142640888691, 0.1396031677722931, 0.16134607791900635, 0.09685184061527252, 0.004910407587885857, -0.09249531477689743, -0.12414124608039856, -0.019530534744262695, -0.19288820028305054, -0.05288580805063248, 0.03045206516981125, -0.0466361939907074, -0.07161886990070343, -0.0032010688446462154, -0.09107936918735504, -0.0780666172504425, -0.09480468928813934, 0.03703638166189194, -0.0029471376910805702, 0.01048612967133522, 0.04230645298957825, -0.02910313755273819, 0.02410072274506092, -0.1362116038799286, -0.09817422926425934, -0.0239171851426363], "changes": {"1wk": 1.2832324763725946}}, {"text": "PREMIUM Exelixis Reports Results on Drug Study to Treat Advanced Gastrointestinal Neuroendocrine Tumors MT Newswires Fri, Jan 24, 2025, 11:42 PM 1 min read In This Article: EXEL -0.81% Exelixis (EXEL) said a phase 3 study showed its cabozantinib drug reduced the risk of disease progre PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EXEL", "date": "2025-01-24T20:42:39+00:00", "sentiment": {"score": 0.07140212506055832, "confidence": 0.08384065330028534, "probabilities": {"positive": 0.08384065330028534, "negative": 0.01243852823972702, "neutral": 0.9037208557128906}}, "embedding": [-0.0312701053917408, -0.07830504328012466, -0.1516316533088684, 0.02109663560986519, -0.01919141784310341, -0.1241949051618576, 0.02625981904566288, 0.14037488400936127, 0.019930116832256317, 0.04303869977593422, 0.014561093412339687, 0.0751560777425766, 0.04429924488067627, -0.06597058475017548, -0.05535237491130829, 0.055873434990644455, 0.10451532155275345, -0.03183998912572861, 0.044576358050107956, 0.07083239406347275, -0.1967037320137024, -0.10437805205583572, 0.2477862685918808, 0.053813863545656204, -0.06725270301103592, -0.05793151631951332, -0.1289079636335373, 0.050606098026037216, -0.06254027038812637, -0.05246546119451523, 0.08217483758926392, -0.031264569610357285, 0.034951839596033096, -0.08978086709976196, 0.03994062915444374, -0.09694104641675949, -0.09744402766227722, 0.06705969572067261, -0.14856521785259247, 0.01148285809904337, 0.09250352531671524, -0.0955505520105362, -0.10241346806287766, 0.1345328539609909, -0.023077866062521935, -0.2920296788215637, -0.18908356130123138, 0.0049157398752868176, 0.06451550126075745, 0.17774194478988647, -0.13210563361644745, -0.2366054356098175, 0.06356383860111237, 0.06554353982210159, 0.012221593409776688, -0.06196920573711395, -0.1653071939945221, -0.08970814198255539, -0.07990031689405441, 0.0604751892387867, -0.009480700828135014, 0.04432857781648636, -0.11597037315368652, 0.03328757733106613, 0.11770869046449661, 0.17881859838962555, -0.0030213603749871254, 0.013148932717740536, -0.030784012749791145, -0.01033454667776823, 0.05731252208352089, -0.09295989573001862, -0.03999151661992073, 0.08656695485115051, -0.047349873930215836, 0.130350723862648, 0.14396345615386963, 0.10093078762292862, 0.008467997424304485, -0.08499190211296082, 0.05444728210568428, 0.14791366457939148, 0.0995647981762886, -0.02990444377064705, 0.08087180554866791, 0.03862205520272255, 0.03238063305616379, 0.07745078951120377, -0.07136658579111099, 0.03247286379337311, 0.1665567010641098, -0.015260199084877968, -0.010581756941974163, -0.025927621871232986, 0.043826740235090256, -0.1036648228764534, -0.18501277267932892, -0.16975872218608856, -0.08931723237037659, -0.02579732984304428, 0.01942974142730236, 0.0015742762479931116, -0.10408736765384674, -0.06744296103715897, -0.1460081785917282, -0.1310316026210785, 0.13040684163570404, 0.08351875096559525, -0.03523184359073639, -0.03721487149596214, -0.10511914640665054, 0.007254520896822214, 0.009464853443205357, -0.06185717135667801, -0.04182357341051102, 0.2735018730163574, -0.0569649301469326, 0.06574037671089172, 0.17742031812667847, -0.04214921593666077, -0.0487678125500679, 0.15451891720294952, 0.0035764891654253006, -0.019193217158317566, 0.13229188323020935, 0.03031613491475582, -0.08918742835521698, 1.472974502132976e-32, 0.04258180782198906, -0.03841147944331169, 0.13622191548347473, 0.07382854074239731, 0.16121211647987366, 0.21077142655849457, -0.039400845766067505, -0.10569783300161362, -0.09138981997966766, -0.08178166300058365, -0.19221225380897522, 0.0073339082300662994, 0.09287139028310776, 0.2096916288137436, -0.08613574504852295, -0.07269559800624847, -0.21189762651920319, 0.11488320678472519, 0.07219503074884415, 0.029947461560368538, 0.08688157796859741, -0.10095258802175522, 0.038400474935770035, -0.10395332425832748, -0.19516879320144653, 0.1803540587425232, -0.039357930421829224, 0.20837311446666718, 0.1439976692199707, 0.03890721872448921, -0.13125838339328766, 0.008016861043870449, -0.0026359930634498596, 0.01751292496919632, -0.14882799983024597, 0.17399446666240692, 0.0415724441409111, -0.06421533972024918, 0.06742178648710251, 0.11748471111059189, -0.02066658064723015, 0.005958667024970055, -0.09531878679990768, 0.007887600921094418, 0.03811948746442795, -0.13105182349681854, -0.03669125959277153, -0.1254481077194214, 0.14798395335674286, -0.04760051891207695, 0.0746491327881813, -0.0026680328883230686, -0.10600516200065613, 0.020551934838294983, -0.08490917831659317, 0.10200051963329315, -0.1851571649312973, 0.0641544908285141, 0.142614483833313, -0.024943893775343895, 0.12087319046258926, 0.057544611394405365, 0.11036431044340134, -0.0832371860742569, -0.07954595983028412, 0.11740478128194809, -0.12098076194524765, -0.2136160284280777, -0.10597972571849823, 0.031632062047719955, 0.01766447350382805, -0.0014578521950170398, 0.15126629173755646, 0.05380496010184288, 0.02337927371263504, 0.010098232887685299, -0.062287867069244385, -0.032239750027656555, 0.0465073399245739, 0.12227091938257217, -0.040713194757699966, -0.20973864197731018, 0.031331997364759445, 0.1993735432624817, 0.06198619678616524, 0.1498555690050125, -0.005009073298424482, 0.0358165018260479, -0.01414784137159586, 0.08163896948099136, 0.09403568506240845, 0.023370934650301933, -0.18884103000164032, 0.05722157657146454, 0.05834908410906792, -1.6700921212648084e-32, -0.01170458272099495, 0.06588632613420486, 0.008997981436550617, -0.1905258148908615, -0.10247985273599625, 0.0347047857940197, -0.1714966744184494, 0.007079844828695059, 0.23294998705387115, 0.12133395671844482, 0.0817936360836029, 0.2487962245941162, 0.06359356641769409, -0.10768445581197739, 0.04609234258532524, -0.07132550328969955, -0.12220577895641327, -0.17451748251914978, -0.02170214243233204, -0.0771210566163063, -0.013739592395722866, 0.060439419001340866, -0.20419612526893616, 0.0860099270939827, 0.035218290984630585, 0.010448585264384747, 0.1657181680202484, 0.16371478140354156, -0.021887848153710365, -0.2516898512840271, -0.11698124557733536, 0.11338390409946442, -0.3046071529388428, -0.02693890407681465, 0.06026893109083176, 0.01734304428100586, 0.06798291951417923, -0.04025070741772652, -0.07297682762145996, -0.09591222554445267, -0.08548877388238907, 0.02541206404566765, -0.10906557738780975, -0.010561378672719002, 0.129157155752182, 0.027238493785262108, 0.04040803760290146, -0.08561531454324722, 0.15289361774921417, 0.07286219298839569, -0.020809203386306763, -0.014582529664039612, 0.07780030369758606, 0.017011212185025215, 0.00948773417621851, -0.04449762776494026, -0.09039337933063507, -0.08626443892717361, -0.06892449408769608, 0.09396839886903763, 0.026971828192472458, 0.19363297522068024, -0.11714911460876465, -0.04511447623372078, 0.14491797983646393, 0.08746020495891571, 0.18232125043869019, 0.010705394670367241, 0.11102224141359329, -0.04771783947944641, 0.11809144914150238, -0.0688462033867836, -0.23649060726165771, -0.08190800994634628, -0.016086123883724213, 0.22553758323192596, 0.05370894446969032, 0.06774535775184631, -0.016372114419937134, -0.03993644192814827, 0.147099107503891, -0.0998888909816742, -0.017087779939174652, -0.11960496753454208, 0.0012945551425218582, 0.009317205287516117, 0.027867093682289124, -0.016027327626943588, -0.08411095291376114, 0.05865621939301491, -0.04631906375288963, -0.13938643038272858, -0.22460882365703583, -0.001841478399001062, 0.08235214650630951, -1.0060355748464644e-07, 0.14371374249458313, -0.030759049579501152, -0.024443984031677246, 0.04031407833099365, -0.025316935032606125, -0.052962567657232285, -0.12319809943437576, -0.005264523439109325, -0.0355614572763443, 0.05787166580557823, 0.02650607004761696, 0.0419471375644207, 0.02421802282333374, -0.04734809324145317, -0.060437168926000595, 0.009380211122334003, -0.00017975797527469695, 0.01676882989704609, -0.048789214342832565, -0.04700620472431183, -0.18544262647628784, 0.015720484778285027, 0.12192691117525101, -0.1601666361093521, -0.035925015807151794, -0.11409159749746323, 0.09504871815443039, 0.07429733872413635, 0.035733774304389954, -0.07716914266347885, -0.08434191346168518, -0.015175730921328068, -0.010602313093841076, -0.010212665423750877, -1.5480014553759247e-05, -0.0175191480666399, 0.06115861237049103, 0.06660450994968414, 0.11020458489656448, 0.08691998571157455, 0.057271383702754974, -0.12598440051078796, 0.10597223788499832, -0.029946861788630486, -0.18197721242904663, 0.0265219584107399, -0.19221122562885284, -0.058531973510980606, 0.13897192478179932, -0.03418191149830818, 0.08344431221485138, 0.049716729670763016, 0.11120613664388657, -0.01860206015408039, -0.12512511014938354, 0.1387883722782135, -0.11308562010526657, -0.020672330632805824, -0.017512042075395584, -0.010290887206792831, 0.04296340048313141, -0.1328360140323639, 0.029004182666540146, 0.08043447881937027], "changes": {"1wk": 2.37801245325435}}, {"text": "PREMIUM Exelixis Shares Fall After Downgrade From Oppenheimer MT Newswires Fri, Jan 24, 2025, 10:32 PM Exelixis' (EXEL) shares were down more than 6% in recent Friday trading after Oppenheimer downgraded PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EXEL", "date": "2025-01-24T19:32:09+00:00", "sentiment": {"score": -0.9255746323615313, "confidence": 0.9339895248413086, "probabilities": {"positive": 0.008414892479777336, "negative": 0.9339895248413086, "neutral": 0.057595640420913696}}, "embedding": [-0.08166474103927612, -0.1018274649977684, 0.09572860598564148, 0.2237035483121872, 0.016733400523662567, -0.162342831492424, -0.0028740561101585627, 0.057827673852443695, 0.04472468048334122, -0.014875720255076885, 0.22417056560516357, 0.2245165854692459, 0.06226348876953125, 0.035190124064683914, 0.16375306248664856, 0.0035541041288524866, 0.020569374784827232, -0.08879812061786652, -0.1372186541557312, 0.13591255247592926, -0.30835700035095215, -0.18978196382522583, -0.041945453733205795, -0.03593072295188904, 0.16430725157260895, 0.01754731871187687, -0.17777107656002045, 0.003542528487741947, -0.011901548132300377, -0.14626283943653107, -0.07014665007591248, 0.012873739935457706, 0.04608410224318504, -0.0719098374247551, -0.02711574174463749, -0.10414161533117294, 0.07067772001028061, -0.011063085868954659, 0.08706234395503998, -0.1522091031074524, 0.06661020964384079, 0.029479358345270157, -0.2277640998363495, -0.03921296447515488, -0.22810815274715424, -0.053001463413238525, 0.11114688962697983, 0.048182882368564606, 0.03491650149226189, 0.09189505130052567, 0.0051223658956587315, -0.05433478578925133, 0.11572204530239105, -0.14928992092609406, -0.005626440513879061, 0.01262269914150238, -0.2080969661474228, -0.07887810468673706, 0.008622587658464909, 0.058714043349027634, 0.10567539930343628, -0.11837554723024368, -0.11485566198825836, -0.011710266582667828, -0.029868926852941513, 0.07337614893913269, 0.2765481770038605, 0.06891705840826035, -0.15415184199810028, 0.02808627486228943, -0.007788993418216705, 0.14330852031707764, -0.06866832822561264, -0.0037524402141571045, -0.031963981688022614, 0.3293974995613098, 0.24813412129878998, -0.18800781667232513, 0.012339393608272076, -0.1084977239370346, 0.033710941672325134, 0.032215334475040436, -0.06966832280158997, -0.031428027898073196, 0.1038244292140007, -0.13387145102024078, 0.06615723669528961, -0.08500193804502487, -0.09147107601165771, -0.1723737120628357, 0.1329652965068817, -0.03890605643391609, -0.09426728636026382, 0.15885458886623383, 0.02842406928539276, 0.06713541597127914, -0.1590268462896347, -0.05071168392896652, -0.19595499336719513, 0.04251652956008911, 0.1586887538433075, 0.12308099865913391, -0.10606502741575241, 0.047986600548028946, -0.06549331545829773, -0.30014073848724365, 0.13947494328022003, 0.18135693669319153, -0.05467550829052925, -0.012579938396811485, -0.05787436291575432, -0.0837542712688446, 0.019510196521878242, -0.10849418491125107, -0.1570320725440979, 0.16743580996990204, -0.19398099184036255, -0.0204682145267725, -0.06248458847403526, -0.11097072064876556, -0.062253039330244064, 0.39017605781555176, -0.051229432225227356, 0.1327274590730667, 0.09298421442508698, 0.04303927347064018, -0.014016092754900455, 1.485835145014941e-32, -0.029342738911509514, 0.051919639110565186, 0.010010085068643093, 0.03068644367158413, 0.1325043886899948, 0.018839916214346886, -0.041033174842596054, -0.07071192562580109, -0.19516189396381378, -0.09383764117956161, -0.09486948698759079, 0.19039347767829895, -0.06756367534399033, -0.018347574397921562, 0.09633908420801163, -0.22450722754001617, -0.06735331565141678, 0.05864381417632103, 0.19591903686523438, -0.0014520740369334817, 0.10017216950654984, -0.13155579566955566, -0.07355263829231262, -0.08033021539449692, -0.14152522385120392, 0.16899120807647705, 0.07365730404853821, 0.05856113135814667, -0.08086889982223511, 0.06499452888965607, -0.11027539521455765, 0.10197418183088303, -0.051187701523303986, -0.04081809148192406, 0.037413209676742554, 0.21044303476810455, -0.06963267177343369, 0.06062803044915199, 0.015664704144001007, -0.25943753123283386, -0.04142332077026367, 0.07537900656461716, -0.2596163749694824, 0.0037200276274234056, -0.05897660180926323, -0.05555855482816696, 0.014068196527659893, -0.17837949097156525, 0.24143017828464508, -0.01874835602939129, 0.04320133477449417, 0.06898009777069092, -0.16805022954940796, 0.024309761822223663, -0.1055256798863411, 0.17224924266338348, -0.006725913845002651, 0.06069830060005188, 0.10567852854728699, -0.07469538599252701, 0.1259477138519287, 0.20328731834888458, 0.014456331729888916, -0.1324426680803299, -0.1435370147228241, 0.2014985829591751, -0.010047748684883118, -0.019457511603832245, -0.3712307810783386, 0.2766999900341034, 0.042529407888650894, -0.044767774641513824, 0.10619689524173737, -0.030669117346405983, -0.011356565169990063, 0.0595417283475399, -0.1942240446805954, -0.1175747811794281, 0.16389434039592743, 0.1677524298429489, 0.14437182247638702, -0.1302555650472641, 0.13177500665187836, -0.1003798097372055, -0.06879918277263641, 4.913911106996238e-05, 0.04250060394406319, 0.013105846010148525, 0.009243006817996502, -0.013609609566628933, 0.13903549313545227, -0.21618704497814178, -0.08712794631719589, 0.130369633436203, 0.031277846544981, -1.8006171038017952e-32, -0.08907763659954071, 0.054193153977394104, 0.009065886028110981, -0.08521610498428345, -0.23258276283740997, -0.053254470229148865, -0.039228811860084534, 0.3131862282752991, -0.034332506358623505, 0.2191922962665558, 0.06864816695451736, 0.17675822973251343, -0.04705353081226349, 0.09068020433187485, -0.030733907595276833, -0.05624163895845413, 0.05320268124341965, -0.11583781987428665, 0.19882185757160187, -0.08972896635532379, -0.07657426595687866, 0.11836080998182297, -0.20680655539035797, 0.25410524010658264, 0.20672425627708435, 0.048559173941612244, 0.19772563874721527, 0.17127957940101624, 0.06497136503458023, -0.2960660755634308, -0.05905552953481674, -0.054074112325906754, -0.16296878457069397, 0.07004910707473755, 0.0147807402536273, -0.0002888058661483228, -0.05533839762210846, 0.12222792953252792, -0.11203183233737946, -0.10412509739398956, 0.07639146596193314, 0.05145062133669853, 0.13425298035144806, 0.0515635684132576, 0.18882328271865845, 0.06272462010383606, -0.023166699334979057, -0.19814372062683105, 0.10957339406013489, 0.00930062960833311, 0.012287022545933723, 0.05179958418011665, 0.10331474244594574, 0.12459281831979752, -0.03838500380516052, -0.03861015662550926, 0.02749299257993698, 0.09128919988870621, -0.16572049260139465, -0.016260461881756783, -0.05561322718858719, 0.12001299113035202, 0.005941271781921387, 0.02315121330320835, -0.09430535137653351, 0.0011400107759982347, 0.16094739735126495, 0.004752065986394882, 0.07035510241985321, 0.06206341087818146, 0.19235627353191376, 0.03174639493227005, -0.15678900480270386, -0.3458160161972046, 0.16957595944404602, 0.25771820545196533, -0.17696717381477356, 0.06952317804098129, -0.10331743955612183, -0.05252680554986, 0.17782799899578094, -0.0712200254201889, -0.0449545755982399, 0.103773333132267, -0.06715422123670578, -0.01544551458209753, 0.06942833214998245, 0.08432210981845856, 0.010447009466588497, 0.04547030106186867, -0.13670478761196136, -0.2368066906929016, -0.05295204743742943, 0.06042924523353577, -0.06375405192375183, -1.0040712794534556e-07, -0.025069911032915115, -0.05282142013311386, -0.0017277946462854743, 0.06117209419608116, 0.08852773159742355, -0.033047452569007874, 0.010752728208899498, 0.009887111373245716, 0.07407885789871216, 0.17287226021289825, -0.06579671055078506, -0.17123444378376007, -0.12856435775756836, -0.04364796355366707, -0.10064323246479034, -0.17043805122375488, -0.09846369922161102, -0.0010218600509688258, 0.09584569931030273, -0.16292612254619598, -0.09249519556760788, 0.009674523957073689, 0.25176098942756653, 0.00322846882045269, 0.07171420007944107, 0.02725907601416111, 0.07065672427415848, -0.16541793942451477, 0.0603908970952034, -0.09163369238376617, -0.16775113344192505, -0.03096860833466053, -0.10678853839635849, -0.058860499411821365, -0.14856114983558655, 0.04292166978120804, 0.05535044148564339, 0.051054541021585464, -0.0138704227283597, 0.1143602579832077, -0.0355960875749588, -0.08750743418931961, 0.12679548561573029, -0.02987554296851158, 0.014648737385869026, 0.20320270955562592, -0.20706048607826233, -0.029504988342523575, 0.28560566902160645, -0.09267394989728928, 0.1207156553864479, -0.13266080617904663, -0.04099300131201744, 0.08829327672719955, -0.14435699582099915, -0.11317195743322372, -0.2044060230255127, 0.06117430329322815, -0.12937501072883606, 0.004946052096784115, 0.015220738016068935, -0.1967850774526596, -0.09946731477975845, 0.18536774814128876], "changes": {"1wk": 2.37801245325435}}, {"text": "PREMIUM Oppenheimer Downgrades Exelixis to Perform From Outperform, Adjusts Price Target to $33 From $41 MT Newswires Fri, Jan 24, 2025, 4:13 PM In This Article: EXEL -0.81% Exelixis (EXEL) has an average rating of overweight and mean price target of $35.71, according to an PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EXEL", "date": "2025-01-24T13:13:35+00:00", "sentiment": {"score": 0.042270602658391, "confidence": 0.05648504197597504, "probabilities": {"positive": 0.05648504197597504, "negative": 0.014214439317584038, "neutral": 0.9293004870414734}}, "embedding": [-0.08332499116659164, -0.04150809720158577, -0.044574569910764694, 0.19931332767009735, 0.02303817681968212, -0.19449931383132935, 0.06837961077690125, 0.1647070348262787, 0.06237121671438217, -0.014099487103521824, 0.1621423214673996, 0.058940786868333817, 0.07946040481328964, -0.03913964703679085, 0.14495036005973816, 0.010443612933158875, 0.24960370361804962, -0.06683409959077835, -0.02677920088171959, 0.07210221141576767, -0.11401665955781937, -0.05686050280928612, 0.02240254171192646, -0.038960281759500504, 0.0911049097776413, -0.07235001772642136, -0.12133274972438812, -0.04010118544101715, -0.024260859936475754, -0.16847752034664154, -0.02120451256632805, -0.04287360608577728, 0.08709370344877243, -0.15082931518554688, 0.013153091073036194, -0.15732930600643158, 0.04869302734732628, 0.012766561470925808, -0.07257471233606339, -0.06552786380052567, 0.0536138154566288, 0.021035803481936455, -0.2642670273780823, -0.0978989228606224, -0.20007465779781342, -0.16532282531261444, 0.02028033696115017, 0.15900170803070068, 0.031516727060079575, 0.07330801337957382, -0.03459353744983673, -0.13894905149936676, 0.10347218811511993, -0.11953870207071304, 0.0489526130259037, -0.025167154148221016, -0.13280780613422394, -0.08693613857030869, -0.027241718024015427, 0.028461502864956856, 0.018718978390097618, -0.1076066866517067, -0.1785244345664978, 0.03985780477523804, 0.05493640527129173, 0.020862553268671036, 0.16697493195533752, -0.08558440953493118, -0.06043846160173416, -0.04393700137734413, -0.087981216609478, 0.034889042377471924, 0.09770505130290985, -0.04526438191533089, 0.056941356509923935, 0.2316749095916748, 0.20535996556282043, -0.13324935734272003, 0.022118015214800835, 0.02457650937139988, 0.06190008670091629, -0.10552151501178741, -0.061202894896268845, -0.12172677367925644, 0.24519605934619904, -0.15769419074058533, 0.09550516307353973, 0.05251166224479675, 0.0586576908826828, 0.034201133996248245, 0.04117687791585922, -0.0890047624707222, -0.14333271980285645, 0.06657270342111588, 0.01894124411046505, 0.12327492237091064, -0.12466206401586533, -0.08793424069881439, -0.17295561730861664, 0.040004659444093704, 0.1677256077528, 0.06435952335596085, -0.05221583694219589, 0.04896825551986694, -0.12343259155750275, -0.3012249171733856, 0.08278747648000717, 0.19264622032642365, -0.04231220856308937, 0.008848466910421848, -0.0901281088590622, -0.16171716153621674, 0.0633673295378685, -0.18781325221061707, -0.0710165724158287, 0.05562430992722511, -0.11259908229112625, 0.0049470579251646996, 0.0535266138613224, -0.13195903599262238, -0.07387649267911911, 0.23171477019786835, -0.015641961246728897, 0.17785413563251495, -0.02105662412941456, -0.033173780888319016, -0.125440314412117, 1.1339760372880382e-32, 0.010531873442232609, 0.1864600032567978, -0.03169909492135048, -0.0981529951095581, 0.021148061379790306, 0.17123650014400482, -0.09005775302648544, -0.0013531739823520184, -0.13886286318302155, -0.026675328612327576, -0.03650149703025818, 0.16082236170768738, 0.0019166938727721572, 0.10216782242059708, 0.13494126498699188, -0.17264075577259064, -0.17269112169742584, 0.17645427584648132, 0.19262635707855225, 0.04516180604696274, 0.07500302791595459, -0.18181656301021576, -0.07963727414608002, -0.09056249260902405, -0.08767659217119217, 0.15306422114372253, 0.02806084230542183, 0.03910338133573532, 0.02757232077419758, 0.03023170866072178, -0.10264284908771515, 0.0062983110547065735, -0.016649581491947174, -0.003986278083175421, -0.0029866627883166075, 0.11142552644014359, -0.11466975510120392, -0.08042564243078232, 0.02890198864042759, -0.16336914896965027, -0.09850117564201355, 0.1988726705312729, -0.13642928004264832, -0.007396100554615259, -0.03687698021531105, 0.07140185683965683, 0.06390802562236786, -0.16393817961215973, 0.14220847189426422, -0.09695817530155182, -0.06015325337648392, 0.09609823673963547, -0.12557964026927948, 0.053831685334444046, -0.14108578860759735, 0.12781360745429993, 0.05735345184803009, 0.04624110832810402, 0.15861111879348755, -0.0334312841296196, 0.01851964183151722, 0.22617709636688232, 0.016310330480337143, -0.07388336211442947, -0.06242166832089424, 0.2176964282989502, -0.07626216858625412, -0.06545877456665039, -0.25597673654556274, 0.29701438546180725, 0.13544107973575592, -0.012341246008872986, 0.15548337996006012, -0.08894694596529007, -0.03476531431078911, 0.0249184537678957, -0.11652088165283203, -0.10001549124717712, 0.14060980081558228, 0.15500816702842712, -0.005324953701347113, -0.047909729182720184, 0.0196219589561224, -0.06140667200088501, 0.01011134684085846, -0.00701418612152338, -0.11190362274646759, 0.05436011776328087, 0.023475440219044685, 0.07798285782337189, 0.18097330629825592, -0.16377265751361847, -0.245623379945755, 0.07193181663751602, -0.016032926738262177, -1.2637416504743937e-32, -0.07533950358629227, 0.06133212521672249, 0.17040115594863892, -0.041069429367780685, -0.13275004923343658, 0.013984274119138718, -0.14685460925102234, 0.19126223027706146, 0.14558899402618408, 0.1720888614654541, -0.04083484411239624, 0.20830021798610687, 0.0008884767885319889, 0.10868317633867264, 0.0389135405421257, -0.06630893051624298, -0.08206700533628464, -0.12861372530460358, 0.1110735833644867, -0.15505853295326233, -0.048411209136247635, 0.15209276974201202, -0.12538029253482819, 0.2470279186964035, 0.14705926179885864, 0.0003881137236021459, 0.1322607398033142, 0.14905284345149994, -0.002397091593593359, -0.30168700218200684, -0.03973869979381561, 0.01289388071745634, -0.06611029803752899, 0.06256259977817535, -0.06999814510345459, 0.10195787996053696, 0.06295942515134811, 0.09250867366790771, -0.03217301145195961, -0.08003175258636475, 0.07644420117139816, 0.04005735367536545, 0.0210050567984581, -0.10894683748483658, 0.1438778191804886, -0.078079454600811, -0.08149918168783188, -0.17422500252723694, 0.12587057054042816, -0.031052976846694946, -0.06833670288324356, 0.027668649330735207, 0.03444916009902954, 0.07824480533599854, -0.17794208228588104, -0.12692396342754364, -0.053716111928224564, 0.15897075831890106, -0.026197245344519615, -0.04454726353287697, 0.056933507323265076, 0.23931193351745605, 0.02717369608581066, 0.037909213453531265, -0.1253521591424942, -0.008885360322892666, 0.2116086483001709, -0.018237149342894554, -0.025275375694036484, 0.028511065989732742, 0.0344754233956337, -0.022992705926299095, -0.04239244759082794, -0.17369800806045532, 0.09046655893325806, 0.14508765935897827, -0.00014197149721439928, 0.0003563364443834871, -0.06766406446695328, -0.09925758838653564, 0.14057417213916779, -0.06762397289276123, 0.06945294886827469, -0.00825949665158987, 0.02683393657207489, -0.07898889482021332, 0.0682256892323494, 0.08153646439313889, -0.06143973022699356, 0.10082399845123291, -0.11680872738361359, -0.1068584993481636, -0.034832488745450974, 0.010968683287501335, -0.03900792449712753, -1.0033613762061577e-07, -0.03450615331530571, -0.021552588790655136, 0.022389978170394897, 0.06740032881498337, -0.0005595816182903945, -0.003665344323962927, 0.03578218072652817, -3.7410944742077845e-07, 0.0310429148375988, 0.061718977987766266, 0.10092613101005554, -0.19122688472270966, -0.01901846192777157, 0.02502313256263733, -0.046746354550123215, -0.1230759471654892, -0.10417916625738144, -0.04667513817548752, 0.07305319607257843, -0.10259014368057251, -0.06350081413984299, 0.1520024836063385, 0.1775493323802948, -0.06315609812736511, 0.07712391763925552, 0.07070454210042953, 0.03725074976682663, -0.08984284847974777, 0.1055985614657402, -0.02189517207443714, -0.15047132968902588, -0.003471740521490574, -0.06491643190383911, 0.08314988762140274, -0.09076082706451416, -0.059829339385032654, -0.10562188178300858, 0.11070982366800308, -0.157342791557312, 0.1828603595495224, 0.08622799068689346, -0.09509897977113724, 0.0021519262809306383, -0.015118510462343693, -0.014887179248034954, 0.19565054774284363, -0.337504118680954, -0.09337177872657776, 0.21711847186088562, -0.025980550795793533, 0.1783965528011322, 0.08623746037483215, 0.002352598588913679, 0.09375172853469849, -0.15854790806770325, -0.10311176627874374, -0.1624847948551178, 0.049029283225536346, -0.16139136254787445, 0.14303292334079742, 0.16166222095489502, -0.32489094138145447, 0.017203381285071373, 0.17001932859420776], "changes": {"1wk": 1.698576957744866}}, {"text": "Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025 Business Wire Fri, Jan 24, 2025, 10:30 PM 18 min read In This Article: EXEL -0.81% \u2013 Cabozantinib reduced the risk of disease progression or death by 50 percent compared with placebo in patients with advanced gastrointestinal neuroendocrine tumors \u2013 \u2013 Supplemental New Drug Application under review with the U.S. FDA for cabozantinib for the treatment of patients with advanced neuroendocrine tumors based on findings from CABINET \u2013 ALAMEDA, Calif., January 24, 2025 --( BUSINESS WIRE )-- Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine tumors (epNET) arising in the gastrointestinal (GI) tract. The analysis showed cabozantinib was associated with an improvement in progression-free survival (PFS) compared with placebo in patients with advanced GI neuroendocrine tumors (NET), which was a subgroup of the epNET cohort. These results are being presented today during Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract, at 11:30 a.m. PT on January 24 at the American Society of Clinical Oncology 2025 Gastrointestinal Cancers Symposium (ASCO GI 2025). \"Treating neuroendocrine tumors after disease progression can be challenging, including for those with tumors in the gastrointestinal tract, as treatment options are limited,\" said Jonathan Strosberg, M.D., President Emeritus, North American Neuroendocrine Tumor Society and Chair, GI Research Program, Moffitt Cancer Center and Research Institute. \"This subgroup analysis from the CABINET study showed that cabozantinib improved progression-free survival for patients with tumors arising in the GI tract and provides a more detailed picture of how patients with the most common form of this cancer may benefit from this treatment. As a physician, I\u2019m encouraged by these findings, as they suggest cabozantinib has potential to become a standard of care for patients greatly in need of new options.\" This subgroup analysis included 116 of the 203 patients in the epNET cohort. The most common primary tumor locations were ileum/cecum (54%), small intestine with location not specified (20%), non-cecum colon or rectum (11%), stomach (4%), duodenum (3%), jejunum (3%) and non-specified midgut site (3%). Cabozantinib was associated with improved PFS by blinded independent central review compared with placebo for patients with GI NET (hazard ratio: 0.50; 95% confidence interval: 0.28-0.88; one-sided stratified log-rank P=0.007). Median PFS was 8.5 months with cabozantinib compared with 5.6 months with placebo. Cabozantinib demonstrated potential benefit across clinical factors, including grade, functional status, concurrent somatostatin agent use, and prior therapy with Lu-177 dotatate or everolimus. One patient achieved a partial response with cabozantinib versus none with placebo, and 48 versus 30 patients, respectively, achieved stable disease. Story Continues \"These new data add to the robust results from the CABINET trial that demonstrate the benefits of cabozantinib across a wide range of patients with neuroendocrine tumors and further underscore the potential of cabozantinib to become a much-needed new option for those with GI NET, which accounts for the majority of real-world patients with this tumor type,\" said Amy Peterson, M.D., Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer, Exelixis. \"We look forward to continuing to work with the U.S. FDA as they review our regulatory application for cabozantinib for the treatment of patients with previously treated advanced neuroendocrine tumors.\" The safety profile of cabozantinib observed in patients with GI NET was consistent with its known safety profile; no new safety signals were identified. The most frequent grade 3/4 adverse events included hypertension (19% of patients receiving cabozantinib and 4% receiving placebo), diarrhea (13% and 4%, respectively) and fatigue (10% and 4%). Three grade 5 events occurred in the cabozantinib arm possibly related to cabozantinib: one due to cardiac arrest and two not specified. As announced in August 2023, the Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board unanimously recommended that the CABINET trial be stopped early and unblinded due to the substantial improvement in PFS observed at an interim analysis. Final PFS results were presented at the 2024 European Society of Medical Oncology Congress and published concurrently in the New England Journal of Medicine . In August 2024, Exelixis announced that the U.S. Food and Drug Administration (FDA) had accepted the supplemental New Drug Application (sNDA) for cabozantinib for the treatment of previously treated, advanced NET and assigned a Prescription Drug User Fee Act target action date of April 3, 2025. About CABINET (Alliance A021602) CABINET (Randomized, Double-Blinded Phase III Study of CAB ozantinib versus Placebo I n Patients with Advanced NE uroendocrine T umors After Progression on Prior Therapy) is sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and is being led and conducted by the NCI-funded Alliance for Clinical Trials in Oncology with participation from the NCI-funded National Clinical Trials Network as part of Exelixis\u2019 collaboration through a Cooperative Research and Development Agreement with the NCI\u2019s Cancer Therapy Evaluation Program. CABINET is a multicenter, randomized, double-blinded, placebo-controlled phase 3 pivotal trial that had enrolled a total of 298 patients in the U.S at the time of the final analysis. Patients were randomized 2:1 to cabozantinib (60 mg) or placebo in two separately powered cohorts (pancreatic NET, n=95; epNET, n=203). The epNET cohort included patients with the following primary tumor sites: GI tract, lung, unknown primary sites, and other organs. Each cohort was randomized separately and had its own statistical analysis plan. Patients must have had measurable disease per RECIST 1.1 criteria and must have experienced disease progression or intolerance after at least one U.S. FDA-approved line of prior systemic therapy other than somatostatin analogs. The primary endpoint in each cohort was PFS per RECIST 1.1 by blinded independent central review. Secondary endpoints included overall survival, objective response rate and safety. More information about this trial is available at ClinicalTrials.gov . About NET NET are cancers that begin in the specialized cells of the body\u2019s neuroendocrine system. 1 These cells have traits of both hormone-producing endocrine cells and nerve cells. 1 In 2024, the estimated prevalence of NET in the U.S. was more than 380,000 people. 2 It is estimated that 161,000 to 192,000 people are living with unresectable, locally advanced or metastatic NET. 2 The number of people diagnosed with NET has been increasing in recent decades. 3 Functional NET release peptide hormones that can cause debilitating symptoms, like diarrhea, hypertension and flushing, which may require focused treatment, while symptoms of non-functional NET are related primarily to tumor growth. 4,5 Most NET take years to develop and grow slowly, but eventually all patients with advanced or metastatic NET will develop refractory and progressing disease. 6,7 NET can develop in any part of the body, but most commonly start in the GI tract or in the lungs, where they have historically been referred to as carcinoid tumors and are more recently called epNET. 1 The five-year survival rates for advanced GI and lung NET tumors are 68% and 55%, respectively. 8,9 NET can also start in the pancreas, where they tend to be more aggressive, with a five-year survival rate of only 23% for advanced disease. 1,10 For advanced NET patients, treatment options include somatostatin analogs, chemotherapy, molecular targeted therapy and peptide-receptor radionuclide therapy. 11 About CABOMETYX \u00ae (cabozantinib) In the U.S., CABOMETYX tablets are approved as monotherapy for the treatment of patients with advanced renal cell carcinoma (RCC) and in combination with nivolumab for patients as a first-line treatment for patients with advanced RCC; for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib, and; for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible. CABOMETYX tablets have also received regulatory approvals in over 65 countries outside the U.S. and Japan, including the European Union. In 2016, Exelixis granted Ipsen Pharma SAS exclusive rights for the commercialization and further clinical development of cabozantinib outside of the U.S. and Japan. In 2017, Exelixis granted exclusive rights to Takeda Pharmaceutical Company Limited for the commercialization and further clinical development of cabozantinib for all future indications in Japan. Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S. CABOMETYX is not indicated as a treatment for NET. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS Hemorrhage: Severe and fatal hemorrhages occurred with CABOMETYX. The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC, HCC, and DTC studies. Discontinue CABOMETYX for Grade 3 or 4 hemorrhage and prior to surgery as recommended. Do not administer CABOMETYX to patients who have a recent history of hemorrhage, including hemoptysis, hematemesis, or melena. Perforations and Fistulas: Fistulas, including fatal cases, occurred in 1% of CABOMETYX patients. Gastrointestinal (GI) perforations, including fatal cases, occurred in 1% of CABOMETYX patients. Monitor patients for signs and symptoms of fistulas and perforations, including abscess and sepsis. Discontinue CABOMETYX in patients who experience a Grade 4 fistula or a GI perforation. Thrombotic Events: CABOMETYX increased the risk of thrombotic events. Venous thromboembolism occurred in 7% (including 4% pulmonary embolism) and arterial thromboembolism in 2% of CABOMETYX patients. Fatal thrombotic events occurred in CABOMETYX patients. Discontinue CABOMETYX in patients who develop an acute myocardial infarction or serious arterial or venous thromboembolic events that require medical intervention. Hypertension and Hypertensive Crisis: CABOMETYX can cause hypertension, including hypertensive crisis. Hypertension was reported in 37% (16% Grade 3 and <1% Grade 4) of CABOMETYX patients. Do not initiate CABOMETYX in patients with uncontrolled hypertension. Monitor blood pressure regularly during CABOMETYX treatment. Withhold CABOMETYX for hypertension that is not adequately controlled with medical management; when controlled, resume at a reduced dose. Permanently discontinue CABOMETYX for severe hypertension that cannot be controlled with anti-hypertensive therapy or for hypertensive crisis. Diarrhea: Diarrhea occurred in 62% of CABOMETYX patients. Grade 3 diarrhea occurred in 10% of CABOMETYX patients. Monitor and manage patients using antidiarrheals as indicated. Withhold CABOMETYX until improvement to \u2264 Grade 1, resume at a reduced dose. Palmar-Plantar Erythrodysesthesia (PPE): PPE occurred in 45% of CABOMETYX patients. Grade 3 PPE occurred in 13% of CABOMETYX patients. Withhold CABOMETYX until improvement to Grade 1 and resume at a reduced dose for intolerable Grade 2 PPE or Grade 3 PPE. Hepatotoxicity: CABOMETYX in combination with nivolumab can cause hepatic toxicity with higher frequencies of Grades 3 and 4 ALT and AST elevations compared to CABOMETYX alone. Monitor liver enzymes before initiation of and periodically throughout treatment. Consider more frequent monitoring of liver enzymes than when the drugs are administered as single agents. For elevated liver enzymes, interrupt CABOMETYX and nivolumab and consider administering corticosteroids. With the combination of CABOMETYX and nivolumab, Grades 3 and 4 increased ALT or AST were seen in 11% of patients. ALT or AST >3 times ULN (Grade \u22652) was reported in 83 patients, of whom 23 (28%) received systemic corticosteroids; ALT or AST resolved to Grades 0-1 in 74 (89%). Among the 44 patients with Grade \u22652 increased ALT or AST who were rechallenged with either CABOMETYX (n=9) or nivolumab (n=11) as a single agent or with both (n=24), recurrence of Grade \u22652 increased ALT or AST was observed in 2 patients receiving CABOMETYX, 2 patients receiving nivolumab, and 7 patients receiving both CABOMETYX and nivolumab. Withhold and resume at a reduced dose based on severity. Adrenal Insufficiency: CABOMETYX in combination with nivolumab can cause primary or secondary adrenal insufficiency. For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold CABOMETYX and/or nivolumab and resume CABOMETYX at a reduced dose depending on severity. Adrenal insufficiency occurred in 4.7% (15/320) of patients with RCC who received CABOMETYX with nivolumab, including Grade 3 (2.2%), and Grade 2 (1.9%) adverse reactions. Adrenal insufficiency led to permanent discontinuation of CABOMETYX and nivolumab in 0.9% and withholding of CABOMETYX and nivolumab in 2.8% of patients with RCC. Approximately 80% (12/15) of patients with adrenal insufficiency received hormone replacement therapy, including systemic corticosteroids. Adrenal insufficiency resolved in 27% (n=4) of the 15 patients. Of the 9 patients in whom CABOMETYX with nivolumab was withheld for adrenal insufficiency, 6 reinstated treatment after symptom improvement; of these, all (n=6) received hormone replacement therapy and 2 had recurrence of adrenal insufficiency. Proteinuria: Proteinuria was observed in 8% of CABOMETYX patients. Monitor urine protein regularly during CABOMETYX treatment. For Grade 2 or 3 proteinuria, withhold CABOMETYX until improvement to \u2264 Grade 1 proteinuria; resume CABOMETYX at a reduced dose. Discontinue CABOMETYX in patients who develop nephrotic syndrome. Osteonecrosis of the Jaw (ONJ): ONJ occurred in <1% of CABOMETYX patients. ONJ can manifest as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration or erosion, persistent jaw pain, or slow healing of the mouth or jaw after dental surgery. Perform an oral examination prior to CABOMETYX initiation and periodically during treatment. Advise patients regarding good oral hygiene practices. Withhold CABOMETYX for at least 3 weeks prior to scheduled dental surgery or invasive dental procedures, if possible. Withhold CABOMETYX for development of ONJ until complete resolution, resume at a reduced dose. Impaired Wound Healing: Wound complications occurred with CABOMETYX. Withhold CABOMETYX for at least 3 weeks prior to elective surgery. Do not administer CABOMETYX for at least 2 weeks after major surgery and until adequate wound healing. The safety of resumption of CABOMETYX after resolution of wound healing complications has not been established. Reversible Posterior Leukoencephalopathy Syndrome (RPLS): RPLS, a syndrome of subcortical vasogenic edema diagnosed by characteristic findings on MRI, can occur with CABOMETYX. Evaluate for RPLS in patients presenting with seizures, headache, visual disturbances, confusion, or altered mental function. Discontinue CABOMETYX in patients who develop RPLS. Thyroid Dysfunction: Thyroid dysfunction, primarily hypothyroidism, has been observed with CABOMETYX. Based on the safety population, thyroid dysfunction occurred in 19% of patients treated with CABOMETYX, including Grade 3 in 0.4% of patients. Patients should be assessed for signs of thyroid dysfunction prior to the initiation of CABOMETYX and monitored for signs and symptoms of thyroid dysfunction during CABOMETYX treatment. Thyroid function testing and management of dysfunction should be performed as clinically indicated. Hypocalcemia: CABOMETYX can cause hypocalcemia. Based on the safety population, hypocalcemia occurred in 13% of patients treated with CABOMETYX, including Grade 3 in 2% and Grade 4 in 1% of patients. Laboratory abnormality data were not collected in CABOSUN. In COSMIC-311, hypocalcemia occurred in 36% of patients treated with CABOMETYX, including Grade 3 in 6% and Grade 4 in 3% of patients. Monitor blood calcium levels and replace calcium as necessary during treatment. Withhold and resume at reduced dose upon recovery or permanently discontinue CABOMETYX depending on severity. Embryo-Fetal Toxicity: CABOMETYX can cause fetal harm. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Verify the pregnancy status of females of reproductive potential prior to initiating CABOMETYX and advise them to use effective contraception during treatment and for 4 months after the last dose. ADVERSE REACTIONS The most common (\u226520%) adverse reactions are: CABOMETYX as a single agent: diarrhea, fatigue, PPE, decreased appetite, hypertension, nausea, vomiting, weight decreased, and constipation. CABOMETYX in combination with nivolumab: diarrhea, fatigue, hepatotoxicity, PPE, stomatitis, rash, hypertension, hypothyroidism, musculoskeletal pain, decreased appetite, nausea, dysgeusia, abdominal pain, cough, and upper respiratory tract infection. DRUG INTERACTIONS Strong CYP3A4 Inhibitors: If coadministration with strong CYP3A4 inhibitors cannot be avoided, reduce the CABOMETYX dosage. Avoid grapefruit or grapefruit juice. Strong CYP3A4 Inducers: If coadministration with strong CYP3A4 inducers cannot be avoided, increase the CABOMETYX dosage. Avoid St. John\u2019s wort. USE IN SPECIFIC POPULATIONS Lactation: Advise women not to breastfeed during CABOMETYX treatment and for 4 months after the final dose. Hepatic Impairment: In patients with moderate hepatic impairment, reduce the CABOMETYX dosage. Avoid CABOMETYX in patients with severe hepatic impairment. Please see accompanying full Prescribing Information https://www.cabometyx.com/downloads/CABOMETYXUSPI.pdf . You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088. About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX \u00ae (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com , follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements related to: the presentation of detailed results from the CABINET trial at ASCO GI 2025; the therapeutic potential of cabozantinib as a treatment across a wide range of patients with neuroendocrine tumors and the potential of cabozantinib to become a much-needed new option for those with GI NET; the regulatory review process with respect to Exelixis\u2019 sNDA for cabozantinib in previously treated advanced NET, including the Prescription Drug User Fee Act target action date assigned by the FDA; and Exelixis\u2019 scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis\u2019 current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the availability of data at the referenced times; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere; Exelixis\u2019 continuing compliance with applicable legal and regulatory requirements; the potential failure of cabozantinib to demonstrate safety and/or efficacy in future clinical testing; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating cabozantinib; the costs of conducting clinical trials; Exelixis\u2019 dependence on third-party vendors for the development, manufacture and supply of cabozantinib; Exelixis\u2019 ability to protect its intellectual property rights; market competition, including the potential for competitors to obtain approval for generic versions of CABOMETYX; changes in economic and business conditions; and other factors affecting Exelixis and its development programs detailed from time to time under the caption \"Risk Factors\" in Exelixis\u2019 most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis\u2019 future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law. Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis. # # # _______________________________ 1 Neuroendocrine Tumors. Cleveland Clinic website. Available at: https://my.clevelandclinic.org/health/diseases/22006-neuroendocrine-tumors-net . Accessed January 2025. 2 Population Estimate: Unresectable, Locally Advanced or Metastatic Extra-Pancreatic NET. June 2024 (internal data on file). 3 Pathak, S., Starr, J.S., Halfdanarson T., et al. Understanding the increasing incidence of neuroendocrine tumors. Expert Rev Endocrinol Metab. September 2023;18(5):377-385. 4 Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ\u00ae)\u2013Patient Version. NCI website. Available at: https://www.cancer.gov/types/pancreatic/patient/pnet-treatment-pdq . Accessed January 2025. 5 What Is a Pancreatic Neuroendocrine Tumor? ACS website. Available at: https://www.cancer.org/cancer/types/pancreatic-neuroendocrine-tumor/about/what-is-pnet.html . Accessed January 2025. 6 McClellan, K., Chen. E.Y, Kardosh A., et al. Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors. Cancers. 2022, 14(19), 4769. 7 What is a Gastrointestinal Carcinoid Tumor? ACS website. Available at: https://www.cancer.org/cancer/types/gastrointestinal-carcinoid-tumor/about/what-is-gastrointestinal-carcinoid.html . Accessed January 2025. 8 Survival Rates for Gastrointestinal Carcinoid Tumors. ACS website. Available at: https://www.cancer.org/cancer/types/gastrointestinal-carcinoid-tumor/detection-diagnosis-staging/survival-rates.html . Accessed January 2025. 9 Survival Rates for Lung Carcinoid Tumors. ACS website. Available at: https://www.cancer.org/cancer/types/lung-carcinoid-tumor/detection-diagnosis-staging/survival-rates.html . Accessed January 2025. 10 Survival Rates for Pancreatic Neuroendocrine Tumor. ACS website. Available at: https://www.cancer.org/cancer/types/pancreatic-neuroendocrine-tumor/detection-diagnosis-staging/survival-rates.html . Accessed January 2025. 11 Neuroendocrine Tumor (NET). NCI website. Available at: https://www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/rare-endocrine-tumor/carcinoid-tumor . Accessed January 2025. View source version on businesswire.com: https://www.businesswire.com/news/home/20250123418184/en/ Contacts Investors: Susan Hubbard EVP, Public Affairs and Investor Relations Exelixis, Inc. (650) 837-8194 shubbard@exelixis.com Media: Claire McConnaughey Senior Director, Public Affairs Exelixis, Inc. (650) 837-7052 cmcconn@exelixis.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EXEL", "date": "2025-01-24T19:30:00+00:00", "sentiment": {"score": 0.6193171925842762, "confidence": 0.6401166915893555, "probabilities": {"positive": 0.6401166915893555, "negative": 0.02079949900507927, "neutral": 0.339083731174469}}, "embedding": [0.012323053553700447, -0.18366345763206482, -0.06184404715895653, -0.1302194595336914, -0.08393619954586029, -0.09530724585056305, 0.053631462156772614, 0.06698233634233475, 0.06399566680192947, -0.016522353515028954, -0.09804166108369827, 0.0937962457537651, 0.07048225402832031, -0.041651688516139984, -0.06757239997386932, 0.04399796575307846, 0.08928030729293823, -0.03370337560772896, -0.050687387585639954, 0.048981279134750366, -0.03895164653658867, -0.0725155770778656, 0.2527400255203247, 0.06561450660228729, -0.08354875445365906, -0.1389768272638321, -0.09330102801322937, 0.041842471808195114, -0.212755486369133, -0.00017090234905481339, 0.04817921295762062, 0.051942963153123856, -0.07414823770523071, -0.02897065505385399, 0.004631534218788147, 0.013058994896709919, -0.13914254307746887, 0.15391486883163452, -0.0727907046675682, -0.0030809883028268814, -0.004655024036765099, 0.003904137061908841, -0.02126472443342209, 0.1364685297012329, 0.020725192502141, -0.2998506724834442, -0.1954883337020874, -0.14178183674812317, 0.039098963141441345, 0.02779431641101837, -0.06012745574116707, -0.06521560996770859, 0.005863230675458908, 0.2528291940689087, 0.07763107866048813, -0.01765243336558342, -0.0977628231048584, -0.04456496983766556, -0.0337267741560936, -0.03508676588535309, -0.05445432662963867, 0.027744710445404053, -0.0567798838019371, -0.023513704538345337, 0.24160657823085785, 0.11254356801509857, 0.04321756213903427, -0.06890407204627991, -0.11475364863872528, 0.030703574419021606, 0.1294165551662445, -0.10939131677150726, -0.10714270174503326, 0.08245502412319183, -0.0877484530210495, 0.04434029012918472, 0.13915175199508667, 0.2844144403934479, 0.04575031250715256, -0.06708419322967529, 0.042018767446279526, 0.23325461149215698, 0.12167461961507797, -0.0784788429737091, -0.07415493577718735, 0.07067035883665085, -0.040206316858530045, 0.16749361157417297, -0.020163996145129204, 0.015915345400571823, 0.12059731036424637, 0.06934171915054321, 0.02607792243361473, -0.10074002295732498, 0.1576135754585266, -0.2378910481929779, -0.1059807687997818, -0.08437733352184296, 0.07611800730228424, -0.05037960037589073, 0.02923419512808323, -0.09099198877811432, -0.06544575840234756, -0.11290296912193298, -0.013648053631186485, 0.0006628241389989853, 0.04101662337779999, 0.03688981011509895, 0.0033654177095741034, -0.013901116326451302, -0.06571194529533386, 0.029498456045985222, 0.024097200483083725, 0.025347016751766205, -0.031955379992723465, 0.19978855550289154, -0.0045264894142746925, 0.1157531887292862, 0.22550256550312042, 0.049674488604068756, -0.07102552056312561, 0.0761386826634407, 0.09224759042263031, 0.025988895446062088, 0.04350011795759201, 0.10399595648050308, -0.05915433540940285, 1.4270968677987022e-32, 0.005007575266063213, -0.17121979594230652, 0.1424049437046051, 0.029700975865125656, 0.10579680651426315, 0.12356260418891907, -0.02601643092930317, 0.06172861531376839, -0.04044035077095032, -0.036254629492759705, -0.15085236728191376, 0.0448370985686779, 0.03151923418045044, 0.11647091805934906, -0.08889120817184448, -0.07440532743930817, -0.06995189934968948, -0.028180312365293503, -0.05006454885005951, -0.12291443347930908, -0.06356113404035568, -0.0155640859156847, 0.06886668503284454, -0.07323703169822693, -0.08594462275505066, 0.022677967324852943, -0.10694082081317902, 0.2476315200328827, -0.0530855618417263, 0.0025956500321626663, -0.08254648745059967, 0.0517159104347229, 0.07646098732948303, 0.005794069729745388, -0.23559921979904175, -0.04962178319692612, -0.028786994516849518, -0.018992796540260315, 0.10914578288793564, 0.15450428426265717, -0.010806435719132423, -0.049054987728595734, -0.06308718025684357, 0.03326144069433212, 0.002033146098256111, -0.2046712040901184, 0.02393152005970478, -0.05267256870865822, 0.039866913110017776, 0.07271082699298859, 0.031818464398384094, -0.07830804586410522, -0.09462675452232361, -0.03511761501431465, -0.166628897190094, 0.05603870749473572, -0.13519485294818878, 0.04216676205396652, 0.16329368948936462, 0.04717017710208893, 0.062214195728302, 0.08070504665374756, 0.017147015780210495, -0.03369053453207016, -0.024289444088935852, 0.13128197193145752, -0.10175532847642899, -0.1301611363887787, 0.01907852105796337, -0.020840801298618317, -0.07324360311031342, -0.07472992688417435, 0.21546250581741333, 0.10867457091808319, 0.12741738557815552, -0.07918314635753632, -0.05659397691488266, -0.024442244321107864, -0.08052068948745728, 0.09828697144985199, -0.15288418531417847, -0.1456884741783142, -0.09169422835111618, 0.17852160334587097, 0.06376795470714569, 0.0585140734910965, 0.07743221521377563, -0.04925168305635452, -0.11463436484336853, 0.11933280527591705, 0.0989021509885788, -0.022540900856256485, -0.06928983330726624, 0.06756733357906342, 0.1834794580936432, -1.482901845799258e-32, 0.047641001641750336, 0.009086711332201958, -0.042676396667957306, -0.10031633824110031, -0.0049344273284077644, 0.004696957767009735, -0.005394246894866228, -0.1812497079372406, 0.0538795031607151, -0.13213016092777252, 0.018466118723154068, 0.20416250824928284, 0.07565338164567947, -0.10591629147529602, -0.0411788746714592, -0.015919102355837822, -0.19048354029655457, -0.014107533730566502, -0.048547130078077316, 0.06215974688529968, 0.06154518947005272, 0.04013586789369583, -0.2504470944404602, -0.08956670761108398, -0.08897127211093903, 0.0668494701385498, 0.13489162921905518, 0.15834909677505493, 0.04590495303273201, -0.15298932790756226, -0.10268941521644592, 0.13490352034568787, -0.27138856053352356, -0.022508306428790092, 0.0527988001704216, -0.07216764241456985, 0.014888212084770203, -0.16004067659378052, -0.08097267150878906, -0.04017080366611481, -0.07986186444759369, 0.10379883646965027, -0.03917957469820976, -0.006466272287070751, 0.08605335652828217, 0.021022170782089233, 0.10151048749685287, -0.050684355199337006, 0.1114899218082428, 0.10451146215200424, -0.015645496547222137, 0.03730205073952675, 0.04082624986767769, 0.05393308028578758, 0.04173858463764191, 0.027368824928998947, -0.07452046871185303, -0.061614952981472015, -0.08004841208457947, 0.03231259807944298, 0.01633218303322792, 0.14357805252075195, 0.024624772369861603, 0.04074849933385849, 0.3064156174659729, 0.09280741214752197, 0.040649376809597015, -0.00043239258229732513, 0.02694510854780674, 0.0033495365642011166, -0.052341997623443604, -0.08962108194828033, -0.06794213503599167, -0.050434283912181854, -0.050363000482320786, 0.19795095920562744, 0.08585143089294434, 0.024292130023241043, 0.03734544664621353, -0.059803105890750885, 0.018220752477645874, -0.03716433793306351, -0.1327347457408905, -0.06983079016208649, 0.013547442853450775, 0.11948690563440323, -0.011157410219311714, -0.02650860883295536, 0.05322682112455368, 0.05374482274055481, 0.05918555334210396, -0.12513872981071472, -0.09173426032066345, -0.02538817562162876, -0.007965696044266224, -1.0039846642939665e-07, 0.12234415113925934, -0.02423839271068573, -0.10542881488800049, 0.02507910318672657, 0.0977535992860794, -0.08390472084283829, 0.005609783343970776, -0.023174181580543518, 0.018337810412049294, 0.07889802008867264, 0.07863418757915497, 0.11111629009246826, -0.009560823440551758, -0.06574640423059464, -0.1428845226764679, 0.08886384218931198, -0.05020821839570999, -0.021932903677225113, -0.01321336068212986, 0.08091242611408234, -0.1592704802751541, -0.09462566673755646, 0.03252778947353363, -0.10622374713420868, 0.02130039595067501, -0.08161073178052902, 0.08962732553482056, 0.2135525643825531, -0.061783913522958755, -0.04744672775268555, -0.056937120854854584, -0.10273100435733795, 0.02075383812189102, -0.03834950923919678, 0.0897403433918953, 0.030133161693811417, 0.013776722364127636, 0.06316487491130829, 0.11141873151063919, 0.0960870161652565, 0.05583567917346954, -0.14479348063468933, 0.009509607218205929, -0.07194247096776962, -0.0258171446621418, -0.027109814807772636, -0.1892338991165161, 0.09548205137252808, 0.02020084299147129, 0.014080937951803207, 0.019975610077381134, 0.05616927519440651, 0.010656822472810745, -0.010715477168560028, 0.014260604046285152, 0.09681922942399979, -0.06866653263568878, 0.02050221711397171, 0.09311151504516602, 0.013758544810116291, -0.06650497764348984, -0.024717554450035095, -0.02617659792304039, -0.0739932656288147], "changes": {"1wk": 2.37801245325435}}, {"text": "EXEL vs. TECH: Which Stock Is the Better Value Option? Zacks Equity Research Tue, Jan 21, 2025, 7:40 PM 2 min read In This Article: EXEL -0.81% Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Techne (TECH). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits. Exelixis and Techne are sporting Zacks Ranks of #2 (Buy) and #4 (Sell), respectively, right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that EXEL has an improving earnings outlook. But this is only part of the picture for value investors. Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels. The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors. EXEL currently has a forward P/E ratio of 17.10, while TECH has a forward P/E of 40.72. We also note that EXEL has a PEG ratio of 0.72. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. TECH currently has a PEG ratio of 5.05. Another notable valuation metric for EXEL is its P/B ratio of 4.54. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, TECH has a P/B of 5.63. These metrics, and several others, help EXEL earn a Value grade of B, while TECH has been given a Value grade of D. EXEL stands above TECH thanks to its solid earnings outlook, and based on these valuation figures, we also feel that EXEL is the superior value option right now. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Exelixis, Inc. (EXEL) : Free Stock Analysis Report Bio-Techne Corp (TECH) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EXEL", "date": "2025-01-21T16:40:10+00:00", "sentiment": {"score": 0.11016993131488562, "confidence": 0.12434124201536179, "probabilities": {"positive": 0.12434124201536179, "negative": 0.01417131070047617, "neutral": 0.8614874482154846}}, "embedding": [-0.1649806797504425, -0.00857106689363718, -0.028864774852991104, -0.027001067996025085, -0.07026258856058121, -0.05409453064203262, 0.13041451573371887, 0.18472090363502502, 0.2447294145822525, 0.0032993098720908165, -0.08265748620033264, 0.05922034755349159, 0.037869907915592194, -0.04487656056880951, 0.04769759997725487, -0.034558914601802826, 0.11217234283685684, -0.009048820473253727, -0.11619977653026581, -0.0046980492770671844, -0.0513121522963047, -0.09110724925994873, 0.13295823335647583, -0.07930275797843933, 0.06870029866695404, -0.06352962553501129, -0.022948233410716057, 0.11755599081516266, -0.11170818656682968, -0.13049083948135376, -0.10915252566337585, 0.19337613880634308, 0.08870641887187958, -0.09603877365589142, -0.20721599459648132, -0.06803163886070251, 0.05107446387410164, 0.12124565243721008, 0.0822664201259613, -0.07483933866024017, -0.08485855162143707, 0.04565612971782684, -0.059660766273736954, -0.03803449496626854, -0.022944923490285873, -0.10352442413568497, -0.020246895030140877, -0.11878398805856705, -0.07440310716629028, 0.004737945273518562, -0.12604838609695435, -0.010783235542476177, -0.0752856582403183, 0.02669786661863327, -0.01107268501073122, 0.11748222261667252, -0.024418460205197334, -0.10747550427913666, 0.06543703377246857, 0.020288920029997826, 0.07056084275245667, -0.030214615166187286, 0.03939729183912277, -0.05638393759727478, 0.18463432788848877, 0.03530725836753845, -0.004403968341648579, -8.365511894226074e-05, -0.12915430963039398, -0.005719863343983889, 0.046376753598451614, -0.04827534407377243, -0.14167597889900208, 0.09255389869213104, -0.11764263361692429, 0.1632908433675766, 0.08894946426153183, 0.03227580711245537, 0.03384637087583542, -0.021936267614364624, 0.06154089793562889, 0.004973102360963821, -0.11400598287582397, -0.07897984236478806, 0.15618380904197693, -0.0502965971827507, 0.08631805330514908, 0.03148011118173599, 0.05697769671678543, 0.13927358388900757, 0.07821127027273178, -0.07505492866039276, -0.14308010041713715, 0.014129964634776115, 0.2717626094818115, 0.07548901438713074, -0.11757511645555496, -0.11106135696172714, -0.039809271693229675, 0.038226112723350525, 0.08448335528373718, 0.1270824670791626, -0.0822981745004654, -0.04691183939576149, 0.01364092342555523, -0.20076286792755127, 0.17744073271751404, 0.0016956668114289641, 0.08812836557626724, -0.07079175859689713, -0.049495961517095566, -0.015323445200920105, -0.07660196721553802, -0.026974918320775032, -0.1338118016719818, 0.008855372667312622, -0.024193262681365013, 0.044625695794820786, 0.11856073886156082, -0.05645465850830078, 0.06920436024665833, 0.12159615010023117, 0.016743453219532967, 0.020328929647803307, 0.028067149221897125, -0.07012392580509186, -0.20606693625450134, 1.1301672886545801e-32, -0.05397695302963257, 0.13498139381408691, 0.02156325802206993, 0.010725665837526321, 0.02339678257703781, 0.05021404102444649, -0.09732764959335327, -0.06745623052120209, -0.04367014393210411, -0.05086229741573334, -0.15313732624053955, 0.21300920844078064, 0.009491114877164364, -0.09053826332092285, 0.14474636316299438, -0.08010672777891159, -0.1669546365737915, 0.06688284873962402, 0.008517013862729073, -0.016795916482806206, 0.1147107481956482, 0.033359695225954056, 0.008427372202277184, -0.062431931495666504, 0.03651009872555733, -0.10754325240850449, -0.14783692359924316, 0.06293438374996185, -0.1660061776638031, 0.031350888311862946, 0.0435841828584671, -0.003402736969292164, 0.03235379606485367, -0.07418414950370789, -0.04814980924129486, -0.07651998102664948, -0.04359539598226547, -0.05036375671625137, 0.19128084182739258, 0.023975148797035217, -0.1373906135559082, 0.11701912432909012, -0.11801718920469284, 0.024159781634807587, -0.04786166176199913, 0.01794886589050293, 0.004375865682959557, -0.016467975452542305, 0.0369885116815567, -0.06288887560367584, 0.002974156988784671, 0.015000498853623867, 0.0006583612412214279, -0.09719119966030121, -0.10007251799106598, 0.10511764883995056, 0.09376130998134613, -0.0056499093770980835, -0.11438453197479248, 0.13972744345664978, 0.010504256002604961, 0.2412308007478714, 0.06917880475521088, -0.13177496194839478, -0.12906596064567566, 0.16245338320732117, 0.028012458235025406, 0.09108603000640869, -0.039284393191337585, 0.1479661911725998, -0.004258961416780949, 0.05920545011758804, 0.1431739330291748, -0.12598322331905365, -0.037617966532707214, 0.03864726051688194, -0.04643126577138901, 0.032366782426834106, -0.031623516231775284, 0.0854845643043518, -0.08144966512918472, 0.005028148647397757, -0.12926922738552094, -0.043404579162597656, -0.06668400019407272, -0.00485947635024786, 0.03689718246459961, 0.030543528497219086, 0.0430731400847435, -0.033442191779613495, 0.037896908819675446, -0.06635121256113052, -0.1908572018146515, 0.06591786444187164, -0.011512651108205318, -1.170628979704234e-32, -0.014650489203631878, 0.05057410150766373, 0.05042698234319687, 0.1520307958126068, 0.023427272215485573, -0.07314720749855042, 0.12161894142627716, -0.07459720969200134, 0.04331117868423462, 0.019093025475740433, 0.05085071176290512, 0.11204794049263, -0.056194938719272614, -0.0401587188243866, 0.03613221272826195, -0.04815320670604706, -0.1189161017537117, -0.11096381396055222, 0.09308651089668274, -0.11209887266159058, 0.08723070472478867, 0.15980121493339539, -0.15025460720062256, 0.13865914940834045, 0.046856239438056946, 0.10438606142997742, -0.11409413814544678, 0.04236811399459839, -0.049060381948947906, -0.1471458077430725, 0.0029376382008194923, -0.011106139048933983, 0.012602021917700768, 0.043422214686870575, -0.05638165771961212, -0.0026024766266345978, 0.060263969004154205, -0.1403997242450714, 0.005867860745638609, 0.13398605585098267, 0.12205860018730164, 0.07137283682823181, -0.014478462748229504, -0.0025740768760442734, 0.05292529985308647, 0.026529788970947266, 0.07224047183990479, -0.05036311596632004, 0.1674022078514099, -0.04726080968976021, 0.16601763665676117, 0.07238271832466125, -0.06387051939964294, 0.11976611614227295, -0.10296736657619476, -0.052668944001197815, -0.10026958584785461, 0.08035289496183395, -0.16901473701000214, 0.12896248698234558, 0.0786423310637474, 0.16301316022872925, 0.1214791089296341, 0.11201585829257965, -0.14706063270568848, -0.021601714193820953, 0.05001305788755417, 0.09085260331630707, -0.10430441796779633, -0.0613575205206871, -0.016643645241856575, -0.08239907026290894, 0.10308867692947388, -0.12063344568014145, 0.0018831973429769278, 0.14197887480258942, 0.06391498446464539, -0.0466311052441597, -0.06606896221637726, -0.028435003012418747, -0.08032959699630737, 0.05193597823381424, -0.04438184201717377, 0.05434313043951988, -0.1532265543937683, 0.19696997106075287, -0.029005514457821846, 0.038868941366672516, 0.008397827856242657, -0.1506578028202057, -0.08751152455806732, -0.21369847655296326, -0.04915224760770798, -0.08326470851898193, -0.13857942819595337, -1.0057677002350829e-07, 0.002454186789691448, -0.14114025235176086, -0.0018886849284172058, -0.04558662325143814, 0.004688464105129242, -0.03203815966844559, -0.04543096199631691, 0.007672585546970367, 0.06685090810060501, 0.12768621742725372, 0.07635584473609924, -0.04339645802974701, -0.2715924382209778, 0.06109593063592911, -0.04204440489411354, 0.02567284181714058, -0.1275913268327713, -0.006904479581862688, -0.013992945663630962, -0.08146625757217407, -0.027191966772079468, 0.057691097259521484, 0.113123320043087, -0.07902507483959198, -0.0075501990504562855, -0.021229516714811325, -0.09174568951129913, -0.14688605070114136, 0.08840970695018768, 0.07522128522396088, 0.07265691459178925, -0.05477253720164299, 0.07372720539569855, 0.04449399188160896, 0.10905496031045914, -0.0023292917758226395, 0.04490120708942413, 0.06660100817680359, -0.03226853907108307, 0.32408779859542847, 0.03562525287270546, -0.10891088098287582, -0.02543172612786293, 0.010717365890741348, 0.025340761989355087, -0.004037263337522745, -0.12466635555028915, 0.18833230435848236, 0.0005341740325093269, -0.10467894375324249, 0.13898302614688873, -0.003254977986216545, -0.08084794133901596, 0.03387642651796341, -0.14660248160362244, 0.017343858256936073, -0.16570283472537994, 0.020937494933605194, -0.10145531594753265, -0.00890940148383379, 0.11702856421470642, -0.19066733121871948, 0.0453072115778923, 0.12405708432197571], "changes": {"1wk": -10.513318141560765}}, {"text": "Exelixis Stock Faces a Reality Check: Will It Hit $41 or Drop to $33? Khac Phu Nguyen Fri, Jan 24, 2025, 9:37 PM 2 min read In This Article: EXEL -0.81% Exelixis ( NASDAQ:EXEL ) just hit a speed bump. Oppenheimer downgraded the stock from Outperform to Perform, dialing back its price target to $33. The reason? Fresh data from ASCO-GI failed to prove that its next-gen cancer drug, zanzalintinib, has a meaningful edge over its blockbuster cabozantinib. That's a red flag for investors banking on the company's pipeline to fuel future growth. But let's not get ahead of ourselvesExelixis still boasts a rock-solid balance sheet, a 96% gross margin, and a stock that's climbed 39% in 2024, outpacing the Nasdaq Biotechnology Index. With cabozantinib sales jumping 11% year-over-year and new label expansions on the horizon, there's plenty to keep bulls interested. Warning! GuruFocus has detected 5 Warning Signs with EXEL. The big question: Can zanzalintinib deliver? Exelixis is going all in, running six pivotal trials across multiple cancers, with results expected in late 2025. Analysts see blockbuster potentialpossibly $5 billion in U.S. sales by 2033but recent setbacks, like the CONTACT-02 trial missing its survival target in metastatic prostate cancer, have some investors wary. Meanwhile, the company's patent fight over cabozantinib is heating up. A favorable court ruling in October could extend exclusivity to 2030, keeping generics at bay and securing a longer revenue runway. But if that ruling gets overturned? The clock on its flagship drug runs out a lot sooner, which would force Exelixis to scramble for new growth drivers. Wall Street is split. JMP Securities is sticking with its $41 target, betting on long-term pipeline success, while Oppenheimer is playing it safe at $33. To boost investor confidence, Exelixis is rolling out a $500 million share buybackalways a bullish signal. The company is guiding for 2025 revenues between $1.95 billion and $2.05 billion, but whether that's enough to keep the rally going depends on two things: zanzalintinib proving itself in trials and cabozantinib holding onto its patent protection. Bottom line? The next 12 months are make-or-break for Exelixis. This article first appeared on GuruFocus . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "EXEL", "date": "2025-01-24T18:37:12+00:00", "sentiment": {"score": 0.31494295597076416, "confidence": 0.602205753326416, "probabilities": {"positive": 0.602205753326416, "negative": 0.28726279735565186, "neutral": 0.1105315163731575}}, "embedding": [-0.11543610692024231, -0.1307201385498047, -0.07115861028432846, -0.01758982054889202, -0.0704345554113388, -0.13524945080280304, 0.0526263564825058, 0.19697488844394684, 0.1209760308265686, 0.05885858088731766, -0.01789078302681446, 0.15170446038246155, 0.10100696980953217, -0.024191971868276596, -0.011888339184224606, 0.04933900386095047, 0.07570193707942963, -0.04781164601445198, -0.05205082148313522, 0.1293519139289856, -0.07191841304302216, -0.06499326974153519, 0.06683099269866943, 0.014860698021948338, -0.05701629817485809, -0.00757270772010088, -0.11492776870727539, 0.01897842064499855, -0.1599542498588562, -0.15636573731899261, 0.06531056761741638, 0.14370308816432953, -0.03002207726240158, -0.08908940851688385, -0.005658110603690147, -0.0644993856549263, -0.0077121686190366745, 0.08270731568336487, 0.10002350807189941, -0.09301446378231049, 0.07018712908029556, -0.09626096487045288, -0.21854567527770996, 0.005407535005360842, -0.020200463011860847, -0.23474547266960144, -0.05410155653953552, -0.00484791724011302, -0.03774325177073479, 0.07110149413347244, -0.1467558592557907, -0.2095830738544464, 0.057106953114271164, 0.036052193492650986, 0.007010811008512974, -0.027009176090359688, -0.12023982405662537, -0.038249023258686066, 0.03123331069946289, 0.10399962961673737, 0.09623768925666809, -0.054275691509246826, -0.034739017486572266, -0.03820834308862686, 0.16667680442333221, 0.04884573072195053, 0.0953105092048645, -0.10740397125482559, -0.028858669102191925, 0.14948368072509766, 0.13524067401885986, -0.048994213342666626, -0.038510389626026154, 0.025894999504089355, -0.021819356828927994, 0.16345778107643127, 0.13668441772460938, 0.06045570969581604, 0.10854567587375641, -0.08173432946205139, 0.09502255916595459, -0.025334395468235016, 0.007890026085078716, -0.15546394884586334, 0.018969396129250526, -0.007022489793598652, 0.053756263107061386, 0.09368008375167847, 0.1055571660399437, 0.02274080365896225, 0.10537171363830566, -0.01762072555720806, -0.02922123484313488, 0.09095743298530579, 0.06325510144233704, 0.01638142392039299, -0.10901249200105667, -0.07473643869161606, -0.044335249811410904, 0.05314046889543533, 0.10900229215621948, 0.050313059240579605, -0.0434117391705513, -0.06721921265125275, -0.051541510969400406, -0.18677537143230438, 0.10328876972198486, -0.015438483096659184, -0.0722794160246849, -0.05685007572174072, -0.09852898865938187, -0.045498400926589966, -0.027909116819500923, -0.05150606855750084, -0.10744757950305939, 0.19861537218093872, -0.03661564737558365, -0.012179693207144737, 0.035973574966192245, -0.043692447245121, 5.227280780673027e-05, 0.1770308017730713, 0.010969605296850204, 0.02249857410788536, 0.10541795194149017, 0.0543164424598217, -0.20291657745838165, 1.279861792254395e-32, -0.014609673991799355, 0.03405715525150299, 0.029272865504026413, -0.02287648804485798, -0.02754032053053379, 0.13250428438186646, -0.0413568913936615, -0.06159404665231705, -0.16176748275756836, -0.06859001517295837, -0.18000000715255737, 0.03816289082169533, 0.026575153693556786, 0.0515410378575325, 0.07089993357658386, -0.10660813748836517, -0.06902968138456345, 0.029662495478987694, 0.021339593455195427, -0.032630350440740585, 0.13956627249717712, -0.10149841010570526, -0.13610926270484924, -0.024862028658390045, -0.029925793409347534, 0.0909966379404068, -0.0552559569478035, 0.11638078093528748, 0.011986508965492249, 0.06405835598707199, -0.10698094964027405, 0.04938247427344322, -0.08257488906383514, -0.057609811425209045, -0.041877977550029755, -0.01031649112701416, -0.13965332508087158, -0.06212076172232628, 0.09568341076374054, 0.022173982113599777, -0.07788396626710892, 0.1739131361246109, -0.1636846661567688, 0.01051661092787981, 0.061455003917217255, -0.01005843561142683, -0.009325907565653324, -0.055967219173908234, -0.021420501172542572, -0.01390633825212717, 0.00851012859493494, 0.05451042205095291, -0.012678598053753376, 0.0003942912444472313, -0.09026633203029633, 0.1001443862915039, -0.0853426530957222, -0.06211962178349495, 0.09803224354982376, 0.07629364728927612, 0.06946825236082077, 0.090233713388443, -0.07192195951938629, 0.042892780154943466, -0.14380896091461182, 0.19637584686279297, 0.05919072777032852, 0.03354267030954361, -0.17461547255516052, 0.1862371861934662, 0.02866288274526596, -0.0590287521481514, 0.132938414812088, -0.05320035666227341, 0.11113090068101883, -0.10742528736591339, -0.005297724157571793, 0.025129981338977814, 0.019497090950608253, 0.054816607385873795, 0.005830517038702965, -0.04483367130160332, -0.01971600018441677, 0.08029834926128387, -0.009297734126448631, -0.010497188195586205, -0.008415278047323227, -0.009485921822488308, -0.08322113007307053, 0.04060947895050049, 0.05776318162679672, -0.12981466948986053, -0.0825914591550827, 0.14017771184444427, -0.019052162766456604, -1.1488375184918966e-32, 0.04669393226504326, 0.03855514898896217, 0.020091954618692398, -0.06280939280986786, -0.08203191310167313, 0.005915816407650709, 0.07371782511472702, -0.04511582851409912, -0.04105745255947113, -0.0225194301456213, 0.030706115067005157, 0.20963704586029053, 0.05275464057922363, 0.04218544811010361, -0.08369190990924835, -0.0681314468383789, -0.0031824400648474693, -0.14938798546791077, 0.11830924451351166, -0.13555924594402313, 0.03375020623207092, 0.054990626871585846, -0.21309033036231995, 0.15757590532302856, -0.041597895324230194, 0.09650485217571259, 0.06407004594802856, 0.041780102998018265, -0.03722000867128372, -0.1395203173160553, -0.15299756824970245, -0.0012657531769946218, -0.12957260012626648, 0.03627755120396614, 0.034642912447452545, 0.03737930208444595, -0.0026009702123701572, -0.13149967789649963, -0.06069520488381386, -0.05220834165811539, 0.03117927350103855, 0.17230018973350525, -0.017671307548880577, -0.054941970854997635, 0.11685610562562943, 0.034045666456222534, 0.1508493423461914, -0.021011942997574806, 0.1616668403148651, 0.04371785372495651, 0.04741403087973595, 0.16626930236816406, -0.03906315565109253, 0.08438388258218765, -0.04430657625198364, 0.016869161278009415, 0.002287698909640312, 0.013877956196665764, -0.1577070653438568, 0.09239690005779266, -0.02792375162243843, 0.12688714265823364, 0.08977416902780533, -0.06291349977254868, 0.0689106360077858, 0.05001881718635559, 0.12517817318439484, 0.015147987753152847, 0.09822289645671844, -0.11311569809913635, 0.10904560983181, -0.07939715683460236, -0.15670153498649597, -0.04802052676677704, 0.015581347048282623, 0.23815478384494781, -0.0038958387449383736, -0.12497465312480927, -0.11196090281009674, -0.05128832906484604, 0.0658588707447052, -0.0396515354514122, 0.057873934507369995, 0.04482852295041084, 0.0316866897046566, 0.06010729819536209, 0.01570930704474449, -0.02795257419347763, -0.005859344266355038, -0.0013904543593525887, -0.0615692064166069, -0.15352389216423035, -0.06880569458007812, 0.08571386337280273, -0.0022759810090065002, -1.00217718568274e-07, 0.030702833086252213, 0.020335044711828232, -0.027120593935251236, -0.019877856597304344, 0.07259704172611237, -0.07203724980354309, -0.0017427830025553703, -0.005412406288087368, 0.1011267900466919, 0.11445251107215881, 0.13580934703350067, 0.06693179160356522, -0.12630939483642578, 0.09212632477283478, -0.060324251651763916, 0.06116565316915512, -0.12434946000576019, -0.061150938272476196, -0.05339258909225464, -0.037182796746492386, -0.1522216945886612, 0.07329244166612625, 0.06649448722600937, -0.0434342622756958, 0.031822334975004196, -0.10066603124141693, 0.00755474716424942, 0.049956824630498886, 0.0286283977329731, 0.02305135503411293, -0.029185201972723007, -0.057499244809150696, 0.07274021208286285, 0.035898055881261826, -0.06602972000837326, -0.10752204060554504, 0.017969869077205658, 0.12915581464767456, 0.04211025312542915, 0.159950852394104, 0.05613209679722786, -0.06266215443611145, 0.03701391443610191, -0.03794947266578674, -0.09222406148910522, -0.057217806577682495, -0.16419708728790283, -0.06900604814291, 0.10954444110393524, -0.05275873467326164, 0.08839605748653412, 0.028713207691907883, -0.0004723668098449707, 0.04384283721446991, -0.008319844491779804, 0.041827209293842316, -0.20963037014007568, -0.008997195400297642, -0.07337221503257751, 0.029334433376789093, 0.0663108378648758, -0.2960444986820221, 0.11113796383142471, 0.1120506301522255], "changes": {"1wk": 2.37801245325435}}]